Genetic	O
mapping	O
of	O
the	O
copper	Modifier
toxicosis	Modifier
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13-p16.	O
Abnormal	O
hepatic	SpecificDisease
copper	SpecificDisease
accumulation	SpecificDisease
is	O
recognized	O
as	O
an	O
inherited	DiseaseClass
disorder	DiseaseClass
in	O
man,	O
mouse,	O
rat	O
and	O
dog.	O
The	O
major	O
cause	O
of	O
hepatic	SpecificDisease
copper	SpecificDisease
accumulation	SpecificDisease
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene,	O
causing	O
Wilson	SpecificDisease
disease	SpecificDisease
(	O
WD	SpecificDisease
).	O
Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat.	O
The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	SpecificDisease
overload	SpecificDisease
disease	O
non-Indian	SpecificDisease
childhood	SpecificDisease
cirrhosis	SpecificDisease
,	O
indicating	O
genetic	O
heterogeneity.	O
By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	SpecificDisease
toxicosis	SpecificDisease
(	O
CT	SpecificDisease
)	O
in	O
Bedlington	O
terriers,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	DiseaseClass
disease	DiseaseClass
.	O
We	O
examined	O
whether	O
the	O
WD	Modifier
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	SpecificDisease
by	O
investigating	O
the	O
chromosomal	O
co-localization	O
of	O
ATP7B	O
and	O
C04107,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH).	O
C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	SpecificDisease
.	O
However,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26,	O
respectively,	O
demonstrating	O
that	O
WD	SpecificDisease
cannot	O
be	O
homologous	O
to	O
CT	SpecificDisease
.	O
The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	SpecificDisease


Molecular	O
analysis	O
of	O
the	O
APC	Modifier
gene	O
in	O
205	O
families:	O
extended	O
genotype-phenotype	O
correlations	O
in	O
FAP	SpecificDisease
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	Modifier
amino	O
acid	O
changes	O
in	O
colorectal	Modifier
cancer	Modifier
predisposition.	O
BACKGROUND/AIMS	O
	O
The	O
development	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
(	O
APC	Modifier
)	O
gene	O
mutations.	O
In	O
this	O
study,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	Modifier
gene	O
was	O
performed	O
to	O
determine	O
genotype-phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	Modifier
mutations	O
in	O
non-FAP	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
METHODS	O
	O
The	O
APC	Modifier
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	Modifier
and	O
15	O
non-FAP	O
colorectal	Modifier
cancer	Modifier
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis,	O
the	O
protein	O
truncation	O
test,	O
and	O
direct	O
sequencing.	O
RESULTS	O
	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	Modifier
group	O
(105	O
patients).	O
Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non-FAP	O
group	O
of	O
colorectal	Modifier
cancer	Modifier
patients.	O
Genotype-phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	Modifier
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups.	O
CONCLUSIONS	O
	O
Extended	O
genotype-phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions.	O
This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	Modifier
and	O
non-FAP	O
colorectal	Modifier
cancer	Modifier

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	SpecificDisease
hydroxylase	SpecificDisease
deficiency	SpecificDisease
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype-based	O
prediction	O
of	O
metabolic	O
phenotype.	O
Phenylketonuria	SpecificDisease
(	O
PKU	SpecificDisease
)	O
and	O
mild	SpecificDisease
hyperphenylalaninemia	SpecificDisease
(	O
MHP	SpecificDisease
)	O
are	O
allelic	DiseaseClass
disorders	DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(PAH).	O
Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	SpecificDisease
deficiency	SpecificDisease
correlate	O
with	O
PAH	O
genotypes.	O
We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers.	O
On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories.	O
We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome.	O
The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79%	O
of	O
the	O
cases,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected.	O
Among	O
the	O
seven	O
contributing	O
centers,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4%	O
-23%	O
(P	O
<.	O
0001),	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype-phenotype	O
inconsistencies.	O
Our	O
data	O
indicate	O
that	O
the	O
PAH-mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	SpecificDisease
deficiency	SpecificDisease
.	O
In	O
the	O
present	O
study,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10,	O
000	O
genotypes,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	SpecificDisease

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG-binding	O
protein	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	Modifier
gene.	O
One	O
model	O
of	O
DM	Modifier
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain-of-function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats.	O
Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein,	O
CUG-binding	O
protein	O
(CUG-BP),	O
may	O
mediate	O
the	O
trans-dominant	O
effect	O
of	O
the	O
RNA.	O
CUG-BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(cTNT)	O
pre-messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing.	O
Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	Modifier
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats.	O
Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG-BP	O
therefore	O
may	O
contribute	O
to	O
DM	Modifier

Maternal	DiseaseClass
disomy	DiseaseClass
and	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(3;15)	O
(p25;q11.2).	O
Maternal	SpecificDisease
uniparental	SpecificDisease
disomy	SpecificDisease
(UPD)	SpecificDisease
for	SpecificDisease
chromosome	SpecificDisease
15	SpecificDisease
is	O
responsible	O
for	O
an	O
estimated	O
30%	O
of	O
cases	O
of	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	SpecificDisease
disomy	SpecificDisease
15	SpecificDisease
in	O
PWS	SpecificDisease
that	O
is	O
most	O
consistent	O
with	O
adjacent-1	O
segregation	O
of	O
a	O
paternal	O
t	O
(3;	O
15)	O
(p25;	O
q11.	O
2)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15.	O
The	O
patient	O
(J.	O
B.),	O
a	O
17-year-old	O
white	O
male	O
with	O
PWS	SpecificDisease
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary,	O
paternal	O
der	O
(15)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15,	O
and	O
distal	O
chromosome	O
arm	O
3p.	O
The	O
t	O
(3;	O
15)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister.	O
Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	Modifier
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	Modifier
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J.	O
B.	O
Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein-associated	O
polypeptide	O
N	O
(SNRPN)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J.	O
B.	O
Maternal	DiseaseClass
disomy	DiseaseClass
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma-aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(GABRB3)	O
locus.	O
A	O
niece	O
(B.	O
B.)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(15)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p.	O
Uniparental	DiseaseClass
disomy	DiseaseClass
associated	O
with	O
unbalanced	O
segregation	O
of	O
non-Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not,	O
to	O
our	O
knowledge,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	SpecificDisease
.	O
Furthermore,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	SpecificDisease
UPD	SpecificDisease
15	SpecificDisease
and	O
PWS	SpecificDisease

Segregation	O
distortion	O
in	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disease	DiseaseClass
which,	O
in	O
the	O
typical	O
pedigree,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade.	O
This	O
results	O
in	O
infertility	SpecificDisease
and	O
congenital	SpecificDisease
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
CDM	SpecificDisease
)	O
with	O
the	O
disappearance	O
of	O
DM	SpecificDisease
in	O
that	O
pedigree.	O
The	O
concept	O
of	O
segregation	O
distortion,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	Modifier
locus,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	SpecificDisease
in	O
the	O
population.	O
In	O
a	O
survey	O
of	O
DM	SpecificDisease
in	O
Northern	O
Ireland,	O
59	O
pedigrees	O
were	O
ascertained.	O
Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	Modifier
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring.	O
Where	O
the	O
transmitting	O
parent	O
was	O
male,	O
58.	O
3%	O
of	O
the	O
offspring	O
were	O
affected,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent,	O
68.	O
7%	O
were	O
affected.	O
Studies	O
on	O
meiotic	O
drive	O
in	O
DM	SpecificDisease
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	Modifier
locus	O
in	O
non-DM	O
heterozygotes	O
for	O
CTGn.	O
This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	Modifier

Ataxia-telangiectasia	SpecificDisease
:	O
identification	O
and	O
detection	O
of	O
founder-effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations.	O
To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases,	O
such	O
as	O
breast	SpecificDisease
cancer	SpecificDisease
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia-telangiectasia	Modifier
(	O
A-T	Modifier
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations.	O
Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized.	O
Protein-truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(66%)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened.	O
The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist.	O
Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations.	O
These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76%	O
of	O
Costa	O
Rican	O
patients	O
(3),	O
50%	O
of	O
Norwegian	O
patients	O
(1),	O
25%	O
of	O
Polish	O
patients	O
(4),	O
and	O
14%	O
of	O
Italian	O
patients	O
(1),	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish/Mennonite	O
and	O
Irish	O
English	O
backgrounds.	O
Additional	O
mutations	O
were	O
observed	O
in	O
Japanese,	O
Utah	O
Mormon,	O
and	O
African	O
American	O
patients.	O
These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A-T	Modifier

Constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	SpecificDisease
retinoblastoma	SpecificDisease
.	O
In	O
most	O
patients	O
with	O
isolated	O
unilateral	SpecificDisease
retinoblastoma	SpecificDisease
,	O
tumor	Modifier
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene.	O
However,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	Modifier
predisposition	O
to	O
their	O
offspring.	O
To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	SpecificDisease
retinoblastoma	SpecificDisease
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	Modifier
tissue.	O
The	O
analysis	O
of	O
tumors	DiseaseClass
from	O
54	O
(71%)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(LOH)	O
at	O
intragenic	O
loci.	O
Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions.	O
For	O
39	O
randomly	O
selected	O
tumors	DiseaseClass
,	O
SSCP,	O
hetero-duplex	O
analysis,	O
sequencing,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations.	O
Mutations	O
were	O
detected	O
in	O
21	O
(91%)	O
of	O
23	O
tumors	DiseaseClass
with	O
LOH.	O
In	O
6	O
(38%)	O
of	O
16	O
tumors	DiseaseClass
without	O
LOH,	O
one	O
mutation	O
was	O
detected,	O
and	O
in	O
9	O
(56%)	O
of	O
the	O
tumors	DiseaseClass
without	O
LOH,	O
both	O
mutations	O
were	O
found.	O
Thus,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	DiseaseClass
of	O
36	O
patients.	O
Thirty-nine	O
of	O
the	O
mutations-including	O
34	O
small	O
mutations,	O
2	O
large	O
structural	O
alterations,	O
and	O
hypermethylation	O
in	O
3	O
tumors-were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA.	O
In	O
6	O
(17%)	O
of	O
the	O
36	O
patients,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity.	O
The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment.	O
In	O
1	O
patient,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood.	O
In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	DiseaseClass
and	O
the	O
other	O
later	O
developed	O
bilateral	SpecificDisease
retinoblastoma	SpecificDisease
.	O
In	O
conclusion,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	SpecificDisease

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	DiseaseClass
eye	DiseaseClass
malformations	DiseaseClass
.	O
Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	SpecificDisease
(	O
congenital	SpecificDisease
absence	SpecificDisease
of	SpecificDisease
the	SpecificDisease
iris	SpecificDisease
),	O
a	O
rare	O
dominant	O
malformation	DiseaseClass
of	DiseaseClass
the	DiseaseClass
eye	DiseaseClass
.	O
The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	Modifier
patients	O
is	O
highly	O
biased,	O
with	O
92%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(nonsense,	O
splicing,	O
insertions	O
and	O
deletions)	O
and	O
just	O
2%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(missense).	O
The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	Modifier
patients.	O
This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	SpecificDisease
.	O
Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	SpecificDisease
pupillae	SpecificDisease
(	O
displaced	SpecificDisease
pupils	SpecificDisease
)	O
and	O
congenital	SpecificDisease
nystagmus	SpecificDisease
(	O
searching	SpecificDisease
gaze	SpecificDisease
),	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	Modifier
phenotypes.	O
Strikingly,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins.	O
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under-representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	DiseaseClass
-related	DiseaseClass
disease	DiseaseClass

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	Modifier
dystrophy	Modifier
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities.	O
A	O
(CTG)	O
nexpansion	O
in	O
the	O
3-untranslated	O
region	O
(UTR)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(DMPK)	O
is	O
responsible	O
for	O
causing	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
).	O
Major	O
instability,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism,	O
is	O
observed	O
in	O
patients.	O
There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(at	O
least	O
in	O
leucocytes),	O
clinical	O
severity	O
and	O
age	O
of	O
onset.	O
The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	SpecificDisease
and	O
other	O
human	O
genetic	DiseaseClass
diseases	DiseaseClass
are	O
unknown.	O
We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(CTG)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	Modifier
region,	O
using	O
small-pool	O
PCR.	O
These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms.	O
As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	Modifier

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia-telangiectasia	Modifier
families	O
in	O
the	O
British	O
Isles:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	SpecificDisease
,	O
lymphoma	SpecificDisease
,	O
and	O
breast	SpecificDisease
cancer	SpecificDisease
.	O
We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia-telangiectasia	Modifier
(	O
A-T	Modifier
)	O
patients	O
in	O
the	O
British	O
Isles.	O
Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles,	O
11	O
were	O
founder	O
mutations,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	SpecificDisease
degeneration	SpecificDisease
and	O
cellular	O
features.	O
We	O
report,	O
in	O
two	O
A-T	Modifier
families,	O
an	O
ATM	O
mutation	O
(7271T--	O
>	O
G)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(relative	O
risk	O
12.	O
7;	O
P	O
=.	O
0025),	O
although	O
there	O
is	O
a	O
less	O
severe	O
A-T	Modifier
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	SpecificDisease
degeneration	SpecificDisease
.	O
This	O
mutation	O
(7271T--	O
>	O
G)	O
also	O
allows	O
expression	O
of	O
full-length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals.	O
In	O
addition,	O
we	O
have	O
studied	O
18	O
A-T	Modifier
patients,	O
in	O
15	O
families,	O
who	O
developed	O
leukemia	SpecificDisease
,	O
lymphoma	SpecificDisease
,	O
preleukemic	O
T-cell	O
proliferation,	O
or	O
Hodgkin	SpecificDisease
lymphoma	SpecificDisease
,	O
mostly	O
in	O
childhood.	O
A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types,	O
including	O
missense	O
mutations	O
and	O
in-frame	O
deletions,	O
were	O
seen	O
in	O
these	O
patients.	O
We	O
also	O
show	O
that	O
25%	O
of	O
all	O
A-T	Modifier

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast/ovarian	Modifier
cancer	Modifier
families.	O
In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast/ovarian	Modifier
cancer	Modifier
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene.	O
We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	Modifier
cancer	Modifier
families	O
and	O
in	O
one	O
breast-ovarian	Modifier
cancer	Modifier
family.	O
among	O
these	O
were	O
one	O
frameshift	O
mutation,	O
one	O
nonsense	O
mutation,	O
one	O
novel	O
splice	O
site	O
mutation,	O
and	O
one	O
missense	O
mutation.	O
The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2.	O
8%	O
of	O
the	O
general	O
population,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated.	O
The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32.	O
3	O
and	O
37.	O
4	O
years,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51.	O
2	O
years.	O
These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast/ovarian	Modifier
cancer	Modifier

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	SpecificDisease
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
Hereditary	Modifier
Ovarian	Modifier
Cancer	Modifier
Clinical	O
Study	O
Group.	O
BACKGROUND	O
	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
Oral	O
contraceptives	O
protect	O
against	O
ovarian	SpecificDisease
cancer	SpecificDisease
in	O
general,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	SpecificDisease
forms	SpecificDisease
of	SpecificDisease
ovarian	SpecificDisease
cancer	SpecificDisease
.	O
METHODS	O
	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	SpecificDisease
ovarian	SpecificDisease
cancer	SpecificDisease
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case-control	O
study.	O
All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(179	O
women)	O
or	O
BRCA2	O
(28	O
women).	O
The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation.	O
Lifetime	O
histories	O
of	O
oral-contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity.	O
RESULTS	O
	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	SpecificDisease
cancer	SpecificDisease
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0.	O
5	O
(95	O
percent	O
confidence	O
interval,	O
0.	O
3	O
to	O
0.	O
8).	O
The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(P	O
for	O
trend,	O
<	O
0.	O
001);	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk.	O
Oral-contraceptive	O
use	O
protected	O
against	O
ovarian	SpecificDisease
cancer	SpecificDisease
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(odds	O
ratio,	O
0.	O
5;	O
95	O
percent	O
confidence	O
interval,	O
0.	O
3	O
to	O
0.	O
9)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(odds	O
ratio,	O
0.	O
4;	O
95	O
percent	O
confidence	O
interval,	O
0.	O
2	O
to	O
1.	O
1).	O
CONCLUSIONS	O
	O
Oral-contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
families.	O
We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	Modifier
cancer	Modifier
-susceptibility	O
genes,	O
BRCA1	O
and	O
BRCA2,	O
in	O
French	O
Canadian	O
breast	Modifier
cancer	Modifier
and	O
breast/ovarian	Modifier
cancer	Modifier
families	O
from	O
Quebec.	O
To	O
identify	O
founder	O
effects,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	Modifier
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations.	O
Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families.	O
Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice.	O
The	O
BRCA1	O
C4446T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation.	O
Together,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation.	O
The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18.	O
7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	SpecificDisease
cancer	SpecificDisease
were	O
also	O
present	O
in	O
the	O
family.	O
The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5.	O
3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
in	O
the	O
family.	O
Interestingly,	O
the	O
presence	O
of	O
a	O
breast	Modifier
cancer	Modifier
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened.	O
Carriers	O
of	O
the	O
same	O
mutation,	O
from	O
different	O
families,	O
shared	O
similar	O
haplotypes,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population.	O
The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	Modifier
cancer	Modifier
and	O
breast/ovarian	Modifier
cancer	Modifier

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant-negative	O
mutants.	O
PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA-binding	O
domains	O
(paired	O
box	O
and	O
homeobox)	O
and	O
a	O
proline-serine-threonine	O
(PST)	O
-rich	O
transactivation	O
domain.	O
PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans.	O
Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes,	O
including	O
aniridia	SpecificDisease
,	O
Peters	SpecificDisease
anomaly	SpecificDisease
,	O
autosomal	SpecificDisease
dominant	SpecificDisease
keratitis	SpecificDisease
,	O
and	O
familial	SpecificDisease
foveal	SpecificDisease
dysplasia	SpecificDisease
.	O
It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	SpecificDisease
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency.	O
However,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C-terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	SpecificDisease
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA-binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain.	O
It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss-of-function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency.	O
Contrary	O
to	O
this	O
theory,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant-negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild-type	O
PAX6.	O
We	O
found	O
that	O
the	O
dominant-negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants.	O
Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3-5-fold	O
higher	O
affinity	O
to	O
various	O
DNA-binding	O
sites	O
when	O
compared	O
with	O
the	O
wild-type	O
PAX6.	O
These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	SpecificDisease

Crystal	O
structure	O
of	O
the	O
hemochromatosis	Modifier
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor.	O
HFE	O
is	O
an	O
MHC-related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron-overload	SpecificDisease
disease	SpecificDisease
	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
.	O
HFE	O
binds	O
to	O
transferrin	O
receptor	O
(TfR)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron-loaded	O
transferrin,	O
implicating	O
HFE	O
in	O
iron	O
metabolism.	O
The	O
2.	O
6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	Modifier

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	Modifier
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells.	O
BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial,	O
early	O
onset	O
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51.	O
Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes.	O
Like	O
BRCA1	O
and	O
RAD51,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation.	O
Thus,	O
BRCA1	O
and	O
BRCA2	O
participate,	O
together,	O
in	O
a	O
pathway	O
(s)	O
associated	O
with	O
the	O
activation	O
of	O
double-strand	O
break	O
repair	O
and/or	O
homologous	O
recombination.	O
Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	CompositeMention
breast	CompositeMention
and/or	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(CYP27):	O
its	O
effects	O
on	O
pre-mRNA	O
splicing	O
and	O
enzyme	O
activity.	O
A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(CYP27)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	SpecificDisease
xanthomatosis	SpecificDisease
(	O
CTX	SpecificDisease
).	O
The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(CGT	O
362Arg	O
to	O
AGT	O
362Ser),	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27-hydroxylase	O
activity,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS-1	O
cells.	O
Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52.	O
5%	O
of	O
the	O
normal	O
level.	O
As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(-2	O
position	O
of	O
exon	O
6-intron	O
6	O
splice	O
site)	O
of	O
the	O
gene,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient.	O
Transfection	O
of	O
constructed	O
minigenes,	O
with	O
or	O
without	O
the	O
mutation,	O
into	O
COS-1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6.	O
Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	SpecificDisease
in	SpecificDisease
the	SpecificDisease
sterol	SpecificDisease
27-hydroxylase	SpecificDisease
activity	SpecificDisease

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	SpecificDisease
with	O
a	O
codon	O
291	O
deletion:	O
a	O
clinical,	O
biochemical,	O
pathological,	O
and	O
genetic	O
report.	O
We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	SpecificDisease
(	O
ALD	SpecificDisease
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(delGAG	O
291)	O
in	O
the	O
ALD	Modifier
gene.	O
A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family.	O
While	O
the	O
proband	O
(patient	O
1)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello-brain	O
stem	O
forms,	O
his	O
younger	O
brother	O
(patient	O
2)	O
and	O
nephew	O
(patient	O
3)	O
had	O
a	O
childhood	O
ALD	Modifier
type.	O
Another	O
nephew	O
(patient	O
4)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form.	O
The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(CSF)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	SpecificDisease
disease	SpecificDisease
(	O
AD	SpecificDisease
).	O
His	O
brain	O
magnetic	O
resonance	O
image	O
(MRI)	O
showed	O
abnormalities	DiseaseClass
in	DiseaseClass
the	DiseaseClass
bilateral	DiseaseClass
cerebellar	DiseaseClass
hemispheres	DiseaseClass
and	O
brain	O
stem,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(PET).	O
In	O
patients	O
2	O
and	O
3,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	DiseaseClass
of	DiseaseClass
the	DiseaseClass
cerebral	DiseaseClass
white	DiseaseClass
matter	DiseaseClass
with	O
sparing	O
of	O
the	O
U-fibers,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	SpecificDisease
.	O
Oleic	O
and	O
erucic	O
acids	O
(Lorenzos	O
Oil)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained.	O
The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	SpecificDisease
with	O
phenotypic	O
variations.	O
Moreover,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	DiseaseClass
lesion	DiseaseClass
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(CT)	O
or	O
MRI	O
analysis,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	DiseaseClass
degeneration	DiseaseClass
in	O
ALD	SpecificDisease

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	SpecificDisease
syndrome	SpecificDisease
.	O
Pendred	SpecificDisease
syndrome	SpecificDisease
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
early	O
childhood	O
deafness	SpecificDisease
and	O
goiter	SpecificDisease
.	O
A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred,	O
the	O
disease	O
gene	O
(PDS)	O
was	O
mapped	O
to	O
chromosome	O
7q22-q31.	O
1	O
and,	O
recently,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter.	O
We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	Modifier
gene	O
in	O
patients	O
from	O
14	O
Pendred	Modifier
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations.	O
The	O
mutations	O
include	O
three	O
single	O
base	O
deletions,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations.	O
One	O
missense	O
mutation	O
(L236P)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non-consanguineous	O
families.	O
Another	O
missense	O
mutation	O
(T416P)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families.	O
Pendred	Modifier
patients	O
in	O
three	O
non-consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P.	O
In	O
total,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed.	O
The	O
identification	O
of	O
two	O
frequent	O
PDS	Modifier
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	SpecificDisease
syndrome	SpecificDisease

Aspartylglucosaminuria	SpecificDisease
among	O
Palestinian	O
Arabs.	O
Aspartylglucosaminuria	SpecificDisease
(	O
AGU	SpecificDisease
)	O
is	O
a	O
rare	O
disorder	DiseaseClass
of	DiseaseClass
glycoprotein	DiseaseClass
metabolism	DiseaseClass
caused	O
by	O
the	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
lysosomal	SpecificDisease
enzyme	SpecificDisease
aspartylglucosaminidase	SpecificDisease
(AGA).	O
AGU	SpecificDisease
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect.	O
While	O
very	O
few	O
patients	O
with	O
AGU	SpecificDisease
have	O
been	O
reported	O
from	O
non-Finnish	O
origin,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem.	O
The	O
clinical	O
diagnosis	O
of	O
AGU	SpecificDisease

Mutation	O
spectrum	O
and	O
genotype-phenotype	O
analyses	O
in	O
Cowden	SpecificDisease
disease	SpecificDisease
and	O
Bannayan-Zonana	SpecificDisease
syndrome	SpecificDisease
,	O
two	O
hamartoma	DiseaseClass
syndromes	DiseaseClass
with	O
germline	O
PTEN	O
mutation.	O
The	O
tumour	Modifier
suppressor	O
gene	O
PTEN,	O
which	O
maps	O
to	O
10q23.	O
3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(protein	O
tyrosine	O
phosphatase;	O
PTPase),	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	DiseaseClass
.	O
Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	Modifier
breast,	Modifier
brain,	Modifier
prostate	Modifier
and	Modifier
kidney	Modifier
cancer	Modifier
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	DiseaseClass
such	O
as	O
endometrial	SpecificDisease
carcinomas	SpecificDisease
,	O
malignant	SpecificDisease
melanoma	SpecificDisease
and	O
thyroid	SpecificDisease
tumours	SpecificDisease
.	O
In	O
addition,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	DiseaseClass
syndromes	DiseaseClass
	O
Cowden	SpecificDisease
disease	SpecificDisease
(	O
CD	SpecificDisease
;	O
MIM	O
158350)	O
and	O
Bannayan-Zonana	CompositeMention
(BZS)	CompositeMention
or	CompositeMention
Ruvalcaba-Riley-Smith	CompositeMention
syndrome	CompositeMention
(MIM	O
153480).	O
Constitutive	O
DNA	O
from	O
37	O
CD	Modifier
families	O
and	O
seven	O
BZS	Modifier
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations.	O
PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(81%)	O
CD	Modifier
families,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations,	O
deletions,	O
insertions,	O
a	O
deletion/insertion	O
and	O
splice	O
site	O
mutations.	O
These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN,	O
with	O
the	O
exception	O
of	O
the	O
first,	O
fourth	O
and	O
last	O
exons.	O
A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	SpecificDisease
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif,	O
with	O
13	O
of	O
30	O
(43%)	O
CD	Modifier
mutations	O
identified	O
in	O
this	O
exon.	O
Seven	O
of	O
30	O
(23%)	O
were	O
within	O
the	O
core	O
motif,	O
the	O
majority	O
(five	O
of	O
seven)	O
of	O
which	O
were	O
missense	O
mutations,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region.	O
Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(57%)	O
BZS	Modifier
families	O
studied.	O
Interestingly,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif.	O
It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation,	O
R233X,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	Modifier
families	O
and	O
one	O
BZS	Modifier
family.	O
Genotype-phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	Modifier
families.	O
However,	O
genotype-phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	Modifier
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow-up	O
in	O
independent	O
analyses.	O
The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	Modifier
families	O
with	O
breast	DiseaseClass
disease	DiseaseClass
.	O
A	O
correlation	O
was	O
observed	O
between	O
the	O
presence/absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(unaffected	O
versus	O
benign	O
versus	O
malignant).	O
Specifically	O
and	O
more	O
directly,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	DiseaseClass
breast	DiseaseClass
disease	DiseaseClass
.	O
Secondly,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(central	O
nervous	O
system,	O
thyroid,	O
breast,	O
skin	O
and	O
gastrointestinal	O
tract).	O
However,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	Modifier

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non-Jewish	O
family	O
with	O
hereditary	SpecificDisease
non-polyposis	SpecificDisease
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
We	O
describe	O
a	O
French	O
Canadian	O
hereditary	Modifier
non-polyposis	Modifier
colorectal	Modifier
cancer	Modifier
(	O
HNPCC	Modifier
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1.	O
Interestingly,	O
the	O
I1307K	O
APC	O
polymorphism,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
,	O
is	O
also	O
present	O
in	O
this	O
family.	O
The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self-reported	O
Ashkenazi	O
Jewish	O
origins.	O
In	O
addition,	O
in	O
this	O
family,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	DiseaseClass

Wilms'	Modifier
tumor	Modifier
1	O
and	O
Dax-1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF-1	O
in	O
sex-specific	O
gene	O
expression.	O
Products	O
of	O
steroidogenic	O
factor	O
1	O
(SF-1)	O
and	O
Wilms	Modifier
tumor	Modifier
1	O
(WT1)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation.	O
In	O
males,	O
SF-1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(MIS).	O
Here,	O
we	O
show	O
that	O
WT1	O
-KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF-1	O
to	O
promote	O
MIS	O
expression.	O
In	O
contrast,	O
WT1	O
missense	O
mutations,	O
associated	O
with	O
male	SpecificDisease
pseudohermaphroditism	SpecificDisease
in	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(Cys/Tyr)	O
polymorphism.	O
Recent	O
studies	O
have	O
shown	O
that	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
(	O
HH	SpecificDisease
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4.	O
5	O
Mb	O
telomeric	O
to	O
HLA-A.	O
Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site.	O
We	O
have	O
studied	O
the	O
codon	O
282	O
(Cys/Tyr)	O
polymorphism	O
in	O
different	O
ethnic	O
groups.	O
In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(Indian,	O
Chinese)	O
populations.	O
The	O
highest	O
allele	O
frequency	O
(7.	O
5%)	O
was	O
found	O
in	O
Swedes.	O
Saamis	O
(2%)	O
and	O
Mordvinians	O
(1.	O
8%)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele.	O
Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	SpecificDisease
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data,	O
particularly	O
in	O
Finns.	O
The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	SpecificDisease
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	DiseaseClass

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	SpecificDisease
disease	SpecificDisease
.	O
The	O
first	O
predictive	O
testing	O
for	O
Huntington	SpecificDisease
disease	SpecificDisease
(	O
HD	SpecificDisease
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	SpecificDisease
.	O
Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation,	O
pedigree	O
structure,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members.	O
With	O
direct	O
tests	O
for	O
the	O
HD	Modifier

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	SpecificDisease
disease	SpecificDisease
.	O
Four	O
mutations--R778L,	O
A874V,	O
L1083F,	O
and	O
2304delC--in	O
the	O
copper-transporting	O
enzyme,	O
P-type	O
ATPase	O
(ATP7B),	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	SpecificDisease
disease	SpecificDisease
.	O
Arg778Leu,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied,	O
an	O
allele	O
frequency	O
of	O
37.	O
5%,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations.	O
The	O
novel	O
single	O
nucleotide	O
deletion,	O
2304delC,	O
was	O
found	O
in	O
one	O
patient.	O
Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(2302insC)	O
had	O
been	O
previously	O
described,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	SpecificDisease
disease	SpecificDisease

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	SpecificDisease
recessive	SpecificDisease
Alport	SpecificDisease
syndrome	SpecificDisease
.	O
Autosomal	SpecificDisease
recessive	SpecificDisease
Alport	SpecificDisease
syndrome	SpecificDisease
is	O
a	O
progressive	O
hematuric	SpecificDisease
glomerulonephritis	SpecificDisease
characterized	O
by	O
glomerular	DiseaseClass
basement	DiseaseClass
membrane	DiseaseClass
abnormalities	DiseaseClass
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains,	O
respectively.	O
To	O
date,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information.	O
We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene,	O
a	O
comprehensive	O
gene	O
screen,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	SpecificDisease
recessive	SpecificDisease
Alport	SpecificDisease
syndrome	SpecificDisease

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	SpecificDisease
mellitus	SpecificDisease
and	O
optic	SpecificDisease
atrophy	SpecificDisease
(	O
Wolfram	SpecificDisease
syndrome	SpecificDisease
).	O
Wolfram	SpecificDisease
syndrome	SpecificDisease
(	O
WFS	SpecificDisease
;	O
OMIM	O
222300)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
neurodegenerative	DiseaseClass
disorder	DiseaseClass
defined	O
by	O
young-onset	O
non-immune	O
insulin-dependent	SpecificDisease
diabetes	SpecificDisease
mellitus	SpecificDisease
and	O
progressive	O
optic	SpecificDisease
atrophy	SpecificDisease
.	O
Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families.	O
On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease-associated	O
haplotypes,	O
the	O
WFS	Modifier
gene	O
was	O
localized	O
to	O
a	O
BAC/P1	O
contig	O
of	O
less	O
than	O
250	O
kb.	O
Mutations	O
in	O
a	O
novel	O
gene	O
(WFS1)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	Modifier

Molecular	O
defects	O
leading	O
to	O
human	O
complement	SpecificDisease
component	SpecificDisease
C6	SpecificDisease
deficiency	SpecificDisease
in	O
an	O
African-American	O
family.	O
Complement	SpecificDisease
component	SpecificDisease
C6	SpecificDisease
deficiency	SpecificDisease
(	O
C6D	SpecificDisease
)	O
was	O
diagnosed	O
in	O
a	O
16-year-old	O
African-American	O
male	O
with	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
.	O
The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	SpecificDisease
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	SpecificDisease
or	O
other	O
neisserial	SpecificDisease
infection	SpecificDisease
.	O
By	O
using	O
exon-specific	O
polymerase	O
chain	O
reaction	O
(PCR)/single-strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations.	O
The	O
first,	O
1195delC	O
located	O
in	O
exon	O
7,	O
is	O
a	O
novel	O
mutation,	O
while	O
the	O
second,	O
1936delG	O
in	O
exon	O
12,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	SpecificDisease

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	Modifier
ataxia	Modifier
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	Modifier
gene.	O
Friedreich	SpecificDisease
ataxia	SpecificDisease
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	Modifier

Eye	DiseaseClass
movement	DiseaseClass
abnormalities	DiseaseClass
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	DiseaseClass
ataxia	DiseaseClass
type	DiseaseClass
I	DiseaseClass
.	O
We	O
compared	O
horizontal	O
eye	O
movements	O
(visually	O
guided	O
saccades,	O
antisaccades,	O
and	O
smooth	O
pursuit)	O
in	O
control	O
subjects	O
(n	O
=	O
14)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	DiseaseClass
ataxias	DiseaseClass
type	DiseaseClass
I	DiseaseClass
	O
spinocerebellar	CompositeMention
ataxias	CompositeMention
1	CompositeMention
and	CompositeMention
2	CompositeMention
(	O
SCA1	SpecificDisease
,	O
n	O
=	O
11;	O
SCA2	SpecificDisease
,	O
n	O
=	O
10)	O
and	O
SCA3	SpecificDisease
/	O
Machado-Joseph	SpecificDisease
disease	SpecificDisease
(	O
MJD	SpecificDisease
)	O
(n	O
=	O
16).	O
In	O
SCA1	SpecificDisease
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased,	O
resulting	O
in	O
hypermetria	SpecificDisease
.	O
The	O
smooth	O
pursuit	O
gain	O
was	O
decreased.	O
In	O
SCA2	SpecificDisease
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased.	O
The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset.	O
In	O
addition,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found.	O
In	O
SCA3	SpecificDisease
,	O
gaze-evoked	SpecificDisease
nystagmus	SpecificDisease
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased.	O
Three	O
major	O
criteria,	O
saccade	O
amplitude,	O
saccade	O
velocity,	O
and	O
presence	O
of	O
gaze-evoked	SpecificDisease
nystagmus	SpecificDisease
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90%	O
of	O
the	O
SCA1	SpecificDisease
,	O
90%	O
of	O
the	O
SCA2	SpecificDisease
,	O
and	O
93%	O
of	O
the	O
patients	O
with	O
SCA3	SpecificDisease
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and,	O
therefore,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	SpecificDisease
,	O
SCA2	SpecificDisease
,	O
and	O
SCA3	SpecificDisease

Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia-telangiectasia	Modifier
gene	O
in	O
a	O
sporadic	SpecificDisease
T-cell	SpecificDisease
leukaemia	SpecificDisease
.	O
Ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
)	O
is	O
a	O
recessive	DiseaseClass
multi-system	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22-q23	O
(ref.	O
3).	O
The	O
risk	O
of	O
cancer	DiseaseClass
,	O
especially	O
lymphoid	DiseaseClass
neoplasias	DiseaseClass
,	O
is	O
substantially	O
elevated	O
in	O
A-T	Modifier
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability.	O
By	O
analysing	O
tumour	Modifier
DNA	O
from	O
patients	O
with	O
sporadic	SpecificDisease
T-cell	SpecificDisease
prolymphocytic	SpecificDisease
leukaemia	SpecificDisease
(	O
T-PLL	SpecificDisease
),	O
a	O
rare	O
clonal	DiseaseClass
malignancy	DiseaseClass
with	O
similarities	O
to	O
a	O
mature	SpecificDisease
T-cell	SpecificDisease
leukaemia	SpecificDisease
seen	O
in	O
A-T	SpecificDisease
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T-PLL	SpecificDisease
.	O
In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A-T	SpecificDisease
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	DiseaseClass
were	O
missense	O
mutations.	O
These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM-related	O
proteins	O
in	O
mouse,	O
yeast	O
and	O
Drosophila.	O
The	O
resulting	O
amino-acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition.	O
Two	O
of	O
seventeen	O
mutated	O
T-PLL	SpecificDisease
samples	O
had	O
a	O
previously	O
reported	O
A-T	Modifier
allele.	O
In	O
contrast,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene,	O
suggesting	O
that	O
this	O
tumour	Modifier
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	DiseaseClass
.	O
Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	Modifier
DNA	O
from	O
patients	O
with	O
B-cell	SpecificDisease
non-Hodgkins	SpecificDisease
lymphomas	SpecificDisease
(	O
B-NHL	SpecificDisease
)	O
and	O
a	O
B-NHL	Modifier
cell	O
line.	O
The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss-of-function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	DiseaseClass
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	SpecificDisease
T-PLL	SpecificDisease
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	Modifier
suppressor.	O
As	O
constitutional	O
DNA	O
was	O
not	O
available,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T-PLL	SpecificDisease

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin-neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
.	O
Familial	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
(	O
FNDI	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disease	DiseaseClass
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(AVP)	O
encoded	O
by	O
the	O
AVP-neurophysin	O
II	O
(AVP-NPII)	O
gene	O
on	O
chromosome	O
20p13.	O
In	O
this	O
study,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	SpecificDisease
using	O
direct	O
automated	O
fluorescent,	O
solid	O
phase,	O
single-stranded	O
DNA	O
sequencing	O
of	O
PCR-amplified	O
AVP-NPII	O
DNA.	O
In	O
one	O
of	O
the	O
families,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(Glu)	O
of	O
NPII.	O
The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C-terminal	O
domain	O
of	O
NPII,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone.	O
In	O
the	O
second	O
family,	O
a	O
G279A	O
substitution	O
at	O
position	O
-1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals.	O
This	O
missense	O
mutation,	O
which	O
replaces	O
Ala	O
with	O
Thr,	O
is	O
frequent	O
among	O
FNDI	Modifier

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low-density	O
lipoprotein	O
receptor	O
family.	O
A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin-dependent	Modifier
diabetes	Modifier
mellitus	Modifier
(	O
IDDM	Modifier
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13.	O
Based	O
on	O
its	O
chromosomal	O
position,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	DiseaseClass

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia-telangiectasia	Modifier
patients	O
in	O
the	O
Dutch	O
population.	O
Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	DiseaseClass
recessive	DiseaseClass
disorder	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
).	O
In	O
our	O
study,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A-T	Modifier
patients,	O
including	O
some	O
immigrant	O
populations,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin.	O
Both	O
the	O
protein	O
truncation	O
test	O
(PTT)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(REF)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency,	O
identifying	O
76%	O
and	O
60%	O
of	O
the	O
mutations,	O
respectively.	O
Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote.	O
Seventeen	O
mutations	O
were	O
distinct,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously.	O
Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites.	O
Moreover,	O
a	O
16.	O
7-kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements,	O
was	O
identified.	O
The	O
most	O
frequently	O
found	O
mutation,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A-T	Modifier
individuals,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A-T	Modifier
founder	O
mutation.	O
The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities.	O
In	O
patients	O
of	O
Dutch	O
ethnic	O
origin,	O
however,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified.	O
The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice-site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype.	O
All	O
patients	O
manifested	O
classical	O
A-T	SpecificDisease

Diagnosis	O
of	O
hemochromatosis	SpecificDisease
.	O
If	O
untreated,	O
hemochromatosis	SpecificDisease
can	O
cause	O
serious	O
illness	O
and	O
early	SpecificDisease
death	SpecificDisease
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under-diagnosed.	O
The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level.	O
Once	O
the	O
diagnosis	O
is	O
suspected,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	SpecificDisease
overload	SpecificDisease
.	O
Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	SpecificDisease
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management.	O
A	O
DNA-based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	SpecificDisease
is	O
still	O
being	O
evaluated.	O
Currently,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	SpecificDisease
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease.	O
It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	SpecificDisease
before	O
hepatic	SpecificDisease
cirrhosis	SpecificDisease

PAX6	O
mutations	O
reviewed.	O
Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	SpecificDisease
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	SpecificDisease
anomaly	SpecificDisease
,	O
with	O
congenital	SpecificDisease
cataracts	SpecificDisease
,	O
with	O
autosomal	SpecificDisease
dominant	SpecificDisease
keratitis	SpecificDisease
,	O
and	O
with	O
isolated	SpecificDisease
foveal	SpecificDisease
hypoplasia	SpecificDisease
.	O
No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	SpecificDisease

Schwartz-Jampel	SpecificDisease
syndrome	SpecificDisease
type	SpecificDisease
2	SpecificDisease
and	O
Stuve-Wiedemann	SpecificDisease
syndrome	SpecificDisease
:	O
a	O
case	O
for	O
"lumping".	O
Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz-Jampel	SpecificDisease
syndrome	SpecificDisease
(	O
SJS	SpecificDisease
)	O
of	O
myotonia	SpecificDisease
and	O
skeletal	SpecificDisease
dysplasia	SpecificDisease
,	O
which	O
we	O
called	O
SJS	SpecificDisease
type	SpecificDisease
2	SpecificDisease
.	O
This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition,	O
the	O
Stuve-Wiedemann	SpecificDisease
syndrome	SpecificDisease
(	O
SWS	SpecificDisease
),	O
which	O
comprises	O
campomelia	SpecificDisease
at	O
birth	O
with	O
skeletal	SpecificDisease
dysplasia	SpecificDisease
,	O
contractures	SpecificDisease
,	O
and	O
early	SpecificDisease
death	SpecificDisease
.	O
To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow-up	O
of	O
the	O
only	O
two	O
surviving	O
patients,	O
one	O
with	O
SJS	SpecificDisease
type	SpecificDisease
2	SpecificDisease
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	SpecificDisease
at	O
age	O
7	O
years.	O
Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	SpecificDisease
or	O
SWS	SpecificDisease
presented	O
a	O
combination	O
of	O
a	O
severe,	O
prenatal-onset	O
neuromuscular	DiseaseClass
disorder	DiseaseClass
(with	O
congenital	SpecificDisease
joint	SpecificDisease
contractures	SpecificDisease
,	O
respiratory	O
and	O
feeding	O
difficulties,	O
tendency	O
to	O
hyperthermia	SpecificDisease
,	O
and	O
frequent	O
death	O
in	O
infancy)	O
with	O
a	O
distinct	O
campomelic-metaphyseal	SpecificDisease
skeletal	SpecificDisease
dysplasia	SpecificDisease
.	O
The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity.	O
The	O
follow-up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	SpecificDisease
dysplasia	SpecificDisease
in	O
the	O
two	O
patients	O
(one	O
with	O
SJS	SpecificDisease
type	SpecificDisease
2	SpecificDisease
,	O
one	O
with	O
SWS	SpecificDisease
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity.	O
The	O
hypothesis	O
that	O
SWS	SpecificDisease
and	O
SJS	SpecificDisease
type	SpecificDisease
2	SpecificDisease

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim.	O
The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
and	O
in	O
the	O
general	O
population.	O
All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus.	O
Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern.	O
We	O
extended	O
our	O
analysis	O
to	O
other	O
non-Ashkenazi	O
subsets	O
	O
354	O
of	O
Moroccan	O
origin,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews.	O
Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed.	O
Four	O
of	O
Moroccan	O
origin	O
(1.	O
1%)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation.	O
BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non-Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast/ovarian	CompositeMention
cancer	CompositeMention

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	SpecificDisease
intracranial	SpecificDisease
retinoblastoma	SpecificDisease
.	O
The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	SpecificDisease
intracranial	SpecificDisease
retinoblastoma	SpecificDisease
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	CompositeMention
and	CompositeMention
retinal	CompositeMention
tumours	CompositeMention
of	O
the	O
patient.	O
A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(codon	O
556)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	CompositeMention
and	CompositeMention
the	CompositeMention
pineal	CompositeMention
tumours	CompositeMention
.	O
The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin.	O
The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele.	O
The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein-binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	SpecificDisease

Genomic	O
structure	O
of	O
the	O
human	O
congenital	Modifier
chloride	Modifier
diarrhea	Modifier
(	O
CLD	Modifier
)	O
gene.	O
Congenital	SpecificDisease
chloride	SpecificDisease
diarrhea	SpecificDisease
(	O
CLD	SpecificDisease
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter.	O
We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	Modifier
gene	O
which	O
spans	O
approximately	O
39kb,	O
and	O
comprises	O
21	O
exons.	O
All	O
exon/intron	O
boundaries	O
conform	O
to	O
the	O
GT/AG	O
rule.	O
An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites.	O
The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large-insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	Modifier
patients	O
and	O
controls.	O
Exon-specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease.	O
Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H_RG364P16	O
revealed	O
the	O
presence	O
of	O
another,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	Modifier
gene,	O
with	O
a	O
similar	O
genomic	O
structure,	O
recently	O
identified	O
as	O
the	O
Pendred	Modifier
syndrome	Modifier
gene	O
(	O
PDS	SpecificDisease

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	Modifier
syndrome	Modifier
patients.	O
Angelman	SpecificDisease
syndrome	SpecificDisease
(	O
AS	SpecificDisease
)	O
is	O
caused	O
by	O
chromosome	O
15q11-q13	O
deletions	O
of	O
maternal	O
origin,	O
by	O
paternal	O
uniparental	SpecificDisease
disomy	SpecificDisease
(	O
UPD	SpecificDisease
)	O
15,	O
by	O
imprinting	O
defects,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene.	O
UBE3A	O
encodes	O
a	O
ubiquitin-protein	O
ligase	O
and	O
shows	O
brain-specific	O
imprinting.	O
Here	O
we	O
describe	O
UBE3A	O
coding-region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	Modifier
individuals	O
or	O
families.	O
Two	O
identical	O
de	O
novo	O
5-bp	O
duplications	O
in	O
exon	O
16	O
were	O
found.	O
Among	O
the	O
other	O
11	O
unique	O
mutations,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon,	O
1	O
was	O
a	O
missense	O
mutation,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer.	O
Eight	O
of	O
the	O
cases	O
were	O
familial,	O
and	O
five	O
were	O
sporadic.	O
In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
	O
in	O
the	O
mother	O
of	O
three	O
AS	Modifier
sons,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	Modifier
first	O
cousins,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	Modifier

Autosomal	SpecificDisease
dominant	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23-->Val	O
in	O
neurophysin	O
II.	O
Autosomal	SpecificDisease
dominant	SpecificDisease
neurohypophyseal	SpecificDisease
diabetes	SpecificDisease
insipidus	SpecificDisease
(	O
ADNDI	SpecificDisease
)	O
is	O
an	O
inherited	DiseaseClass
disease	DiseaseClass
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(AVP).	O
Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth,	O
but	O
usually	O
develop	O
diabetes	SpecificDisease
insipidus	SpecificDisease
at	O
1-6	O
yr	O
of	O
age.	O
The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP-neurophysin	O
II	O
(NPII)	O
gene,	O
and	O
mutations	O
that	O
cause	O
ADNDI	SpecificDisease
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro-AVP-NPII	O
precursor	O
and	O
within	O
NPII	O
itself.	O
An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(G1758--	O
>	O
T)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23--	O
>	O
Val	O
within	O
NPII.	O
The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis.	O
A	O
T1-weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot.	O
This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	DiseaseClass
inherited	DiseaseClass
neurodegeneration	DiseaseClass

Reversal	O
of	O
severe	O
hypertrophic	SpecificDisease
cardiomyopathy	SpecificDisease
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very-long-chain	SpecificDisease
acyl-coenzyme	SpecificDisease
A	SpecificDisease
dehydrogenase	SpecificDisease
deficiency	SpecificDisease
.	O
Very-long-chain	SpecificDisease
acyl-coenzyme	SpecificDisease
A	SpecificDisease
dehydrogenase	SpecificDisease
(VLCAD)	SpecificDisease
deficiency	SpecificDisease
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality.	O
We	O
describe	O
the	O
outcome	O
of	O
a	O
5-year-old	O
girl	O
with	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	SpecificDisease
cardiomyopathy	SpecificDisease
,	O
hepatomegaly	SpecificDisease
,	O
encephalopathy	DiseaseClass
,	O
and	O
hypotonia	SpecificDisease
.	O
Biochemical	O
studies	O
indicated	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme.	O
Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(F458L)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation.	O
After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low-fat	O
diet	O
supplemented	O
with	O
medium-chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting.	O
Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year,	O
and	O
cognitively,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age.	O
Clinical	O
recognition	O
of	O
VLCAD	SpecificDisease
deficiency	SpecificDisease
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	DiseaseClass

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia-telangiectasia	Modifier
patients:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5.	O
The	O
ATM	O
(A-T,	O
mutated)	O
gene	O
on	O
human	O
chromosome	O
11q22.	O
3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	DiseaseClass
disease	DiseaseClass
	O
ataxia-telangiectasia	SpecificDisease
(	O
A-T	SpecificDisease
).	O
In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease-causing	O
ATM	O
mutations	O
in	O
Japanese	O
A-T	Modifier
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots,	O
reverse-transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A-T	Modifier

Down-regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	Modifier
cell	Modifier
carcinoma	Modifier
cell	O
lines	O
by	O
wild-type	O
von	Modifier
Hippel-Lindau	Modifier
transgenes.	O
To	O
discover	O
genes	O
involved	O
in	O
von	Modifier
Hippel-Lindau	Modifier
(	O
VHL	Modifier
)	O
-mediated	O
carcinogenesis,	O
we	O
used	O
renal	Modifier
cell	Modifier
carcinoma	Modifier
cell	O
lines	O
stably	O
transfected	O
with	O
wild-type	O
VHL-expressing	O
transgenes.	O
Large-scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene,	O
termed	O
CA12.	O
The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one-pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module.	O
Reintroduced	O
wild-type	O
VHL	SpecificDisease
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	Modifier
cell	Modifier
carcinoma	Modifier
cell	O
lines.	O
Similar	O
results	O
were	O
obtained	O
with	O
CA9,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain.	O
Although	O
both	O
domains	O
of	O
the	O
VHL	Modifier
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression.	O
We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21.	O
2	O
respectively,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	DiseaseClass
.	O
Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	Modifier

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N-acetylgalactosamine-6-sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
.	O
Mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
(	O
MPS	SpecificDisease
IVA	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
N-acetylgalactosamine-6-sulfate	O
sulfatase	O
(GALNS).	O
In	O
previous	O
studies,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese,	O
respectively.	O
To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	Modifier
IVA	Modifier
patients	O
were	O
investigated,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin,	O
based	O
on	O
mitochondrial	O
DNA	O
(mtDNA)	O
lineages.	O
Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	Modifier
IVA	Modifier

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha-subunit	O
of	O
beta-hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G(M2)	SpecificDisease
gangliosidosis	SpecificDisease
.	O
Mutations	O
in	O
the	O
HEXA	O
gene,	O
encoding	O
the	O
alpha-subunit	O
of	O
beta-hexosaminidase	O
A	O
(Hex	O
A),	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
),	O
the	O
fatal	O
infantile	SpecificDisease
form	SpecificDisease
of	SpecificDisease
G	SpecificDisease
(M2)	SpecificDisease
gangliosidosis,	SpecificDisease
Type	SpecificDisease
1	SpecificDisease
.	O
Less	O
severe,	O
subacute	O
(juvenile-onset)	O
and	O
chronic	O
(adult-onset)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity.	O
We	O
identified	O
a	O
1422	O
G--	O
>	O
C	O
(amino	O
acid	O
W474C)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non-Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	SpecificDisease
(M2)	SpecificDisease
gangliosidosis	SpecificDisease
.	O
On	O
the	O
second	O
maternally	O
inherited	O
allele,	O
we	O
identified	O
the	O
common	O
infantile	O
disease-causing	O
4-bp	O
insertion,	O
+	O
TATC	O
1278,	O
in	O
exon	O
11.	O
Pulse-chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C-containing	O
alpha-subunit	O
precursor	O
was	O
normally	O
synthesized,	O
but	O
not	O
phosphorylated	O
or	O
secreted,	O
and	O
the	O
mature	O
lysosomal	O
alpha-subunit	O
was	O
not	O
detected.	O
When	O
the	O
W474C-containing	O
alpha-subunit	O
was	O
transiently	O
co-expressed	O
with	O
the	O
beta-subunit	O
to	O
produce	O
Hex	O
A	O
(alphabeta)	O
in	O
COS-7	O
cells,	O
the	O
mature	O
alpha-subunit	O
was	O
present,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha-subunit	O
transfections,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha-subunit	O
associated	O
with	O
infantile	O
TSD	SpecificDisease
.	O
Furthermore,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha-subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha-subunit	O
precursor	O
levels.	O
We	O
conclude	O
that	O
the	O
1422	O
G--	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	SpecificDisease
A	SpecificDisease
enzyme	SpecificDisease
deficiency	SpecificDisease
in	O
the	O
proband.	O
The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha-subunit	O
processing,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	SpecificDisease
A	SpecificDisease
deficiency	SpecificDisease

Myotonic	Modifier
dystrophy	Modifier
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells.	O
Myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
),	O
the	O
most	O
prevalent	O
muscular	DiseaseClass
disorder	DiseaseClass
in	O
adults,	O
is	O
caused	O
by	O
(CTG)	O
n-repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	Modifier

Insertional	O
mutation	O
by	O
transposable	O
element,	O
L1,	O
in	O
the	O
DMD	Modifier
gene	O
results	O
in	O
X-linked	SpecificDisease
dilated	SpecificDisease
cardiomyopathy	SpecificDisease
.	O
X-linked	SpecificDisease
dilated	SpecificDisease
cardiomyopathy	SpecificDisease
(	O
XLDCM	SpecificDisease
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	DiseaseClass
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	DiseaseClass
involvement	DiseaseClass
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	SpecificDisease
myopathy	SpecificDisease
.	O
To	O
date,	O
several	O
mutations	O
in	O
the	O
Duchenne	Modifier
muscular	Modifier
dystrophy	Modifier
gene,	O
DMD,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	SpecificDisease
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	Modifier
phenotype	O
has	O
remained	O
to	O
be	O
elucidated.	O
We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	Modifier
patients	O
from	O
two	O
unrelated	O
Japanese	O
families.	O
The	O
insertion	O
was	O
a	O
5-truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5-untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration.	O
We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	SpecificDisease

Genetic	O
heterogeneity	O
of	O
Saethre-Chotzen	SpecificDisease
syndrome	SpecificDisease
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations.	O
Thirty-two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre-Chotzen	SpecificDisease
syndrome	SpecificDisease
,	O
a	O
common	O
autosomal	DiseaseClass
dominant	DiseaseClass
condition	DiseaseClass
of	O
craniosynostosis	SpecificDisease
and	O
limb	DiseaseClass
anomalies	DiseaseClass
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST,	O
FGFR2,	O
and	O
FGFR3.	O
Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families.	O
Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269-270	O
deletion.	O
To	O
date,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68%	O
in	O
our	O
Saethre-Chotzen	Modifier
syndrome	Modifier
patients,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations.	O
More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature.	O
The	O
most	O
common	O
phenotypic	O
features,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations,	O
are	O
coronal	SpecificDisease
synostosis	SpecificDisease
,	O
brachycephaly	SpecificDisease
,	O
low	SpecificDisease
frontal	SpecificDisease
hairline	SpecificDisease
,	O
facial	SpecificDisease
asymmetry	SpecificDisease
,	O
ptosis	SpecificDisease
,	O
hypertelorism	SpecificDisease
,	O
broad	SpecificDisease
great	SpecificDisease
toes	SpecificDisease
,	O
and	O
clinodactyly	SpecificDisease
.	O
Significant	O
intra-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations.	O
The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence,	O
in	O
the	O
same	O
genes,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	DiseaseClass
condition	DiseaseClass
-such	O
as	O
Saethre-Chotzen,	CompositeMention
Crouzon,	CompositeMention
and	CompositeMention
Pfeiffer	CompositeMention
syndromes	CompositeMention

Frequent	O
inactivation	O
of	O
PTEN/MMAC1	O
in	O
primary	O
prostate	SpecificDisease
cancer	SpecificDisease
.	O
Sporadic	SpecificDisease
prostate	SpecificDisease
carcinoma	SpecificDisease
is	O
the	O
most	O
common	O
male	DiseaseClass
cancer	DiseaseClass
in	O
the	O
Western	O
world,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	DiseaseClass
remain	O
to	O
be	O
elucidated.	O
Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease
.	O
Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss.	O
A	O
new	O
tumor	Modifier
suppressor	O
gene,	O
PTEN/MMAC1,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	Modifier
cancer	Modifier
cell	O
lines.	O
We	O
screened	O
80	O
prostate	SpecificDisease
tumors	SpecificDisease
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases.	O
We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN/MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity.	O
The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(43%)	O
tumors	DiseaseClass
establishes	O
PTEN/MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	SpecificDisease
prostate	SpecificDisease
cancer	SpecificDisease

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
in	O
Australia	O
and	O
Northern	O
Ireland:	O
nine	O
novel	O
mutations	O
including	O
T312S,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype.	O
Mucopolysaccharidosis	SpecificDisease
IVA	SpecificDisease
(	O
MPS	SpecificDisease
IVA	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
lysosomal	DiseaseClass
storage	DiseaseClass
disorder	DiseaseClass
caused	O
by	O
a	O
genetic	DiseaseClass
defect	DiseaseClass
in	O
N-acetylgalactosamine-6-sulfate	O
sulfatase	O
(GALNS).	O
Previous	O
studies	O
of	O
patients	O
from	O
a	O
British-Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	Modifier
IVA	Modifier
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype.	O
We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	Modifier
IVA	Modifier
patients	O
(15	O
from	O
Australia,	O
8	O
from	O
Northern	O
Ireland),	O
with	O
various	O
clinical	O
phenotypes	O
(severe,	O
16	O
cases;	O
intermediate,	O
4	O
cases;	O
mild,	O
3	O
cases).	O
We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients.	O
One	O
is	O
the	O
T312S	O
mutation,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients.	O
The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype.	O
The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(18%)	O
and	O
6	O
(14%)	O
of	O
44	O
unrelated	O
alleles,	O
respectively.	O
The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation.	O
The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century.	O
Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor.	O
The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family.	O
These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	SpecificDisease
IVA	SpecificDisease

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population.	O
The	O
myotonic	Modifier
dystrophy	Modifier
(	O
DM	Modifier
)	O
mutation	O
is	O
an	O
unstable	O
(CTG)	O
n	O
repeat,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5-37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50-3000	O
copies	O
on	O
DM	Modifier
chromosomes.	O
Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	Modifier
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation.	O
To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	Modifier
mutation	O
exists	O
in	O
the	O
Japanese	O
population,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(CTG)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes.	O
Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	Modifier
alleles	O
were	O
always	O
haplotype	O
A.	O
To	O
find	O
an	O
origin	O
of	O
the	O
(CTG)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	Modifier
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members.	O
The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19-37	O
copies.	O
These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	SpecificDisease
and	O
Friedreichs	SpecificDisease
ataxia	SpecificDisease

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	Modifier
-prone	O
families	O
in	O
France.	O
The	O
French	O
Familial	Modifier
Melanoma	Modifier
Study	O
Group.	O
Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	Modifier
pedigrees,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known.	O
We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	Modifier
-prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(n	O
=	O
20)	O
or	O
families	O
with	O
two	O
affected	O
members,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(n	O
=	O
28),	O
and	O
one	O
additional	O
minor	O
criterion.	O
Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families,	O
while	O
one	O
germline	O
mutation,	O
Arg24His,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene.	O
The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(44%)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide.	O
In	O
summary,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	SpecificDisease
melanoma	SpecificDisease
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	Modifier

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	SpecificDisease
coproporphyria	SpecificDisease
and	O
mutation	O
update.	O
Hereditary	SpecificDisease
coproporphyria	SpecificDisease
(	O
HC	SpecificDisease
)	O
is	O
an	O
acute	O
hepatic	SpecificDisease
porphyria	SpecificDisease
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	SpecificDisease
activity	SpecificDisease
of	SpecificDisease
coproporphyrinogen	SpecificDisease
III	SpecificDisease
oxidase	SpecificDisease
(CPO).	O
Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	DiseaseClass
dysfunction	DiseaseClass
often	O
precipitated	O
by	O
drugs,	O
fasting,	O
cyclical	O
hormonal	O
changes,	O
or	O
infectious	DiseaseClass
diseases	DiseaseClass
.	O
Skin	O
photosensitivity	O
may	O
also	O
be	O
present.	O
The	O
seven	O
exons,	O
the	O
exon/intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon-by-exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	Modifier
patients	O
from	O
France,	O
Holland,	O
and	O
Czech	O
Republic.	O
Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected.	O
Among	O
these	O
mutations	O
	O
two	O
are	O
missense	O
(G197W,	O
W427R),	O
two	O
are	O
nonsense	O
(Q306X,	O
Q385X),	O
two	O
are	O
small	O
deletions	O
(662de14bp;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390),	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(IVS1-15c--	O
>	O
g)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site.	O
The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W,	O
W427R,	O
and	O
the	O
in-frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site-directed	O
mutagenesis.	O
These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity.	O
The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
	O
1)	O
a	O
C/G	O
polymorphism	O
in	O
the	O
promotor	O
region,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(-142C/G),	O
and	O
2)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(+	O
574	O
delATTCTT).	O
Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	SpecificDisease
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	DiseaseClass
defects	DiseaseClass

The	O
haptoglobin-gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	SpecificDisease
.	O
We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(Hp)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	SpecificDisease
.	O
The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(Hp)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin-related	O
gene	O
(Hpr),	O
in	O
tandem	O
from	O
the	O
5	O
side.	O
Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	SpecificDisease
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(Hpdel).	O
In	O
addition,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	SpecificDisease
in	O
three	O
families,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2/Hpdel.	O
The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	Modifier
(Hp2)	O
and	O
Hp2/Hpdel,	O
the	O
mother	O
to	O
be	O
Hp2-1	O
and	O
Hp1/Hp2,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	Modifier
(Hp2)	O
and	O
Hp2/Hpdel,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1/Hpdel,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1.	O
The	O
Hp2/Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(mean	O
+/-SD	O
=	O
0.	O
049	O
+/-0.	O
043	O
mg/ml;	O
n	O
=	O
6),	O
compared	O
with	O
the	O
level	O
(1.	O
64	O
+/-1.	O
07	O
mg/ml)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1/Hpdel	O
was	O
0.	O
50	O
mg/ml,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(1.	O
26	O
+/-0.	O
33	O
mg/ml;	O
n	O
=	O
9),	O
showing	O
a	O
gene-dosage	O
effect.	O
The	O
other	O
allele	O
(Hp2)	O
of	O
individuals	O
with	O
Hp2/Hpdel	O
was	O
found	O
to	O
have,	O
in	O
all	O
exons,	O
no	O
mutation,	O
by	O
DNA	O
sequencing.	O
On	O
the	O
basis	O
of	O
the	O
present	O
study,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	SpecificDisease
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained.	O
However,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	SpecificDisease

Genotype-phenotype	O
correlations	O
in	O
attenuated	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
.	O
Germ-line	O
mutations	O
of	O
the	O
tumor	Modifier
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
(	O
AAPC	SpecificDisease
),	O
a	O
variant	O
of	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
).	O
AAPC	SpecificDisease
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	SpecificDisease
adenomas	SpecificDisease
and	O
a	O
later	O
onset	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
(age	O
>	O
40	O
years).	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype-phenotype	O
correlations	O
in	O
AAPC	Modifier
families.	O
By	O
protein-truncation	O
test	O
(PTT)	O
assay,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	Modifier
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	Modifier
kindreds,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined.	O
Five	O
novel	O
germ-line	O
APC	Modifier
mutations	O
were	O
identified	O
in	O
seven	O
kindreds.	O
Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	Modifier
gene	O
	O
(1)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5,	O
(2)	O
within	O
exon	O
9,	O
and	O
(3)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene.	O
Variability	O
in	O
the	O
number	O
of	O
colorectal	SpecificDisease
adenomas	SpecificDisease
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1,	O
and	O
upper-gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them.	O
In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3,	O
the	O
average	O
number	O
of	O
adenomas	DiseaseClass
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar.	O
In	O
all	O
AAPC	Modifier
kindreds,	O
a	O
predominance	O
of	O
right-sided	O
colorectal	SpecificDisease
adenomas	SpecificDisease
and	O
rectal	Modifier
polyp	Modifier
sparing	O
was	O
observed.	O
No	O
desmoid	SpecificDisease
tumors	SpecificDisease
were	O
found	O
in	O
these	O
kindreds.	O
Our	O
data	O
suggest	O
that,	O
in	O
AAPC	Modifier
families,	O
the	O
location	O
of	O
the	O
APC	Modifier
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression.	O
This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical-management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	Modifier

The	O
APC	Modifier
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	DiseaseClass
tumors	DiseaseClass
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history.	O
Classical	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
)	O
is	O
a	O
high-penetrance	O
autosomal	DiseaseClass
dominant	DiseaseClass
disease	DiseaseClass
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	CompositeMention
adenomas	CompositeMention
and	CompositeMention
carcinoma	CompositeMention
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	Modifier
gene.	O
A	O
variant	O
of	O
FAP	SpecificDisease
is	O
attenuated	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
coli	SpecificDisease
,	O
which	O
results	O
from	O
germ-line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	Modifier
gene.	O
Attenuated	Modifier
adenomatous	Modifier
polyposis	Modifier
coli	Modifier
patients	O
have	O
"	O
multiple	O
"	O
colorectal	SpecificDisease
adenomas	SpecificDisease
(typically	O
fewer	O
than	O
100)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	SpecificDisease
.	O
Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	DiseaseClass
has	O
no	O
mutations	O
in	O
the	O
APC	Modifier
gene,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus,	O
or	O
loci,	O
elsewhere	O
in	O
the	O
genome.	O
Recently,	O
however,	O
a	O
missense	O
variant	O
of	O
APC	SpecificDisease
(I1307K)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	SpecificDisease
tumors	SpecificDisease
,	O
including	O
multiple	O
adenomas	DiseaseClass
,	O
in	O
Ashkenazim.	O
We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	CompositeMention
adenomas	CompositeMention
and/or	CompositeMention
carcinoma	CompositeMention
and	O
analyzed	O
codons	O
1263-1377	O
(exon	O
15G)	O
of	O
the	O
APC	Modifier
gene	O
for	O
germ-line	O
variants.	O
Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected,	O
each	O
of	O
Ashkenazi	O
descent.	O
Four	O
patients	O
had	O
a	O
germ-line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	SpecificDisease
polyps	SpecificDisease
of	SpecificDisease
the	SpecificDisease
colorectum	SpecificDisease
.	O
There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ-line	O
variants	O
of	O
the	O
APC	Modifier
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	CompositeMention
adenomas	CompositeMention
and	CompositeMention
carcinoma	CompositeMention
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	SpecificDisease
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease

The	O
hemochromatosis	Modifier
845	O
G-->A	O
and	O
187	O
C-->G	O
mutations:	O
prevalence	O
in	O
non-Caucasian	O
populations.	O
Hemochromatosis	SpecificDisease
,	O
the	O
inherited	DiseaseClass
disorder	DiseaseClass
of	DiseaseClass
iron	DiseaseClass
metabolism	DiseaseClass
,	O
leads,	O
if	O
untreated,	O
to	O
progressive	O
iron	SpecificDisease
overload	SpecificDisease
and	O
premature	SpecificDisease
death	SpecificDisease
.	O
The	O
hemochromatosis	Modifier
gene,	O
HFE,	O
recently	O
has	O
been	O
identified,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions-cDNA	O
nucleotides	O
845	O
G--	O
>	O
A	O
(C282Y)	O
and	O
187	O
C--	O
>	O
G	O
(H63D).	O
Although	O
hemochromatosis	SpecificDisease

BRCA1	O
required	O
for	O
transcription-coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage.	O
The	O
breast	Modifier
and	Modifier
ovarian	Modifier
cancer	Modifier
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function.	O
Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA-damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair.	O
Here,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	Modifier
in	Modifier
BRCA1	Modifier

A	O
mouse	O
model	O
of	O
severe	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	SpecificDisease
.	O
von	SpecificDisease
Willebrand	SpecificDisease
factor	SpecificDisease
(vWf)	SpecificDisease
deficiency	SpecificDisease
causes	O
severe	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease
in	O
humans.	O
We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting.	O
vWf-deficient	Modifier
mice	O
appeared	O
normal	O
at	O
birth;	O
they	O
were	O
viable	O
and	O
fertile.	O
Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	Modifier
Willebrand	Modifier
antigen	O
II)	O
were	O
detectable	O
in	O
plasma,	O
platelets,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice.	O
The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10%	O
of	O
neonates.	O
As	O
in	O
the	O
human	O
disease,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf.	O
Defective	O
thrombosis	SpecificDisease
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	SpecificDisease
injury	SpecificDisease
.	O
In	O
this	O
model,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy.	O
We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	SpecificDisease
Willebrand	SpecificDisease
disease	SpecificDisease

The	O
von	Modifier
Hippel-Lindau	Modifier
tumor	Modifier
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal.	O
The	O
inactivation	O
of	O
the	O
von	Modifier
Hippel-Lindau	Modifier
(VHL)	Modifier
tumor	Modifier
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	SpecificDisease
cancer	SpecificDisease
syndrome	SpecificDisease
and	O
is	O
associated	O
with	O
sporadic	SpecificDisease
renal	SpecificDisease
cell	SpecificDisease
carcinomas	SpecificDisease
(	O
RCC	SpecificDisease
)	O
and	O
brain	SpecificDisease
hemangioblastomas	SpecificDisease
.	O
VHL-negative	O
786-0	O
RCC	Modifier
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	SpecificDisease
.	O
Remarkably,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture.	O
The	O
786-0	O
cell	O
line,	O
like	O
many	O
cancer	Modifier
cells,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal.	O
Here,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild-type	O
VHL	Modifier
gene	O
restores	O
the	O
ability	O
of	O
VHL-negative	O
RCC	Modifier
cancer	Modifier
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0/quiescence	O
in	O
low	O
serum.	O
Both	O
VHL-positive	O
and	O
VHL-negative	O
RCC	Modifier
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition.	O
The	O
cyclin-dependent	O
kinase	O
inhibitor,	O
p27,	O
accumulates	O
upon	O
serum	O
withdrawal,	O
only	O
in	O
the	O
presence	O
of	O
VHL	SpecificDisease
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein.	O
We	O
propose	O
that	O
the	O
loss	O
of	O
wild-type	O
VHL	Modifier
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum-dependent	O
growth	O
control,	O
which	O
may	O
initiate	O
tumor	Modifier
formation.	O
This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild-type	O
VHL	SpecificDisease
,	O
implicating	O
VHL	SpecificDisease
as	O
the	O
first	O
tumor	Modifier

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	SpecificDisease
C9	SpecificDisease
deficiency	SpecificDisease
.	O
Deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
ninth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
(C9)	O
is	O
the	O
most	O
common	O
complement	DiseaseClass
deficiency	DiseaseClass
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries.	O
We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	SpecificDisease
deficiency	SpecificDisease
in	O
four	O
Japanese	O
C9-deficient	Modifier
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	SpecificDisease
meningitis	SpecificDisease
.	O
Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(CGA--	O
>	O
TGA)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9-deficient	Modifier
individuals.	O
An	O
allele-specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous.	O
The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	SpecificDisease
deficiency	SpecificDisease

Human	SpecificDisease
complement	SpecificDisease
factor	SpecificDisease
H	SpecificDisease
deficiency	SpecificDisease
associated	O
with	O
hemolytic	SpecificDisease
uremic	SpecificDisease
syndrome	SpecificDisease
.	O
This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	SpecificDisease
in	SpecificDisease
the	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
regulatory	SpecificDisease
protein	SpecificDisease
Factor	SpecificDisease
H	SpecificDisease
(FH)	O
in	O
the	O
context	O
of	O
an	O
acute	SpecificDisease
renal	SpecificDisease
disease	SpecificDisease
.	O
Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	SpecificDisease
uremic	SpecificDisease
syndrome	SpecificDisease
(	O
HUS	SpecificDisease
).	O
Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150-kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence,	O
upon	O
immunoblotting,	O
of	O
the	O
42-kD	O
Factor	O
H-like	O
protein	O
1	O
(FHL-1)	O
and	O
other	O
FH-related	O
protein	O
(FHR)	O
bands.	O
Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency.	O
The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family.	O
Factor	SpecificDisease
H	SpecificDisease
deficiency	SpecificDisease
is	O
the	O
only	O
complement	DiseaseClass
deficiency	DiseaseClass
associated	O
with	O
HUS	SpecificDisease
.	O
These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and/or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	SpecificDisease

Cell	O
cycle-dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains.	O
Germ-line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early-onset	O
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	Modifier
suppressor.	O
Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell-cycle	O
regulation.	O
When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate,	O
the	O
steady-state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase.	O
Moreover,	O
in	O
S	O
phase	O
cells,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots.	O
"	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1.	O
Here	O
we	O
show	O
that	O
the	O
steady-state	O
levels	O
of	O
BARD1,	O
unlike	O
those	O
of	O
BRCA1,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression.	O
However,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle,	O
but	O
not	O
during	O
the	O
G1	O
phase.	O
Nevertheless,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1-	O
and	O
S-phase	O
cells.	O
Therefore,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots.	O
This	O
cell	O
cycle-dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1-mediated	O
tumor	Modifier

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	SpecificDisease
ventricular	SpecificDisease
fibrillation	SpecificDisease
.	O
Ventricular	SpecificDisease
fibrillation	SpecificDisease
causes	O
more	O
than	O
300,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone.	O
In	O
approximately	O
5-12%	O
of	O
these	O
cases,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non-cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	SpecificDisease
ventricular	SpecificDisease
fibrillation	SpecificDisease
(	O
IVF	SpecificDisease
).	O
A	O
distinct	O
group	O
of	O
IVF	Modifier
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern.	O
Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	SpecificDisease
death	SpecificDisease
,	O
however,	O
molecular	O
genetic	O
studies	O
of	O
IVF	SpecificDisease
have	O
not	O
yet	O
been	O
done.	O
Because	O
IVF	SpecificDisease
causes	O
cardiac	O
rhythm	O
disturbance,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A.	O
We	O
have	O
now	O
identified	O
a	O
missense	O
mutation,	O
a	O
splice-donor	O
mutation,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	Modifier
families.	O
We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non-functional.	O
Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion-channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	SpecificDisease

Prevalence	O
of	O
the	O
I1307K	O
APC	Modifier
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
BACKGROUND	O
&	O
AIMS	O
	O
Israeli	O
Jews	O
of	O
European	O
birth,	O
i.	O
e.,	O
Ashkenazim,	O
have	O
the	O
highest	O
colorectal	Modifier
cancer	Modifier
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group.	O
The	O
I1307K	O
APC	Modifier
gene	O
variant	O
was	O
found	O
in	O
6.	O
1%	O
of	O
American	O
Jews,	O
28%	O
of	O
their	O
familial	O
colorectal	Modifier
cancer	Modifier
cases,	O
but	O
not	O
in	O
non-Jews.	O
We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
METHODS	O
	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non-European	O
origin,	O
with	O
or	O
without	O
a	O
personal	O
and/or	O
family	O
history	O
of	O
neoplasia	DiseaseClass
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allele-specific	O
oligonucleotide	O
(ASO)	O
method.	O
RESULTS	O
	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	SpecificDisease
cancer	SpecificDisease
,	O
I1307K	O
was	O
found	O
in	O
5.	O
0%	O
of	O
120	O
European	O
and	O
1.	O
6%	O
of	O
188	O
non-European	O
Jews	O
(P	O
=	O
0.	O
08).	O
It	O
occurred	O
in	O
15.	O
4%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	DiseaseClass
(P	O
=	O
0.	O
02)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non-European	O
Jews	O
at	O
increased	O
cancer	Modifier
risk.	O
Colorectal	SpecificDisease
neoplasia	SpecificDisease
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	O
carriers,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	DiseaseClass
.	O
CONCLUSIONS	O
	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal,	CompositeMention
or	CompositeMention
other,	CompositeMention
cancers	CompositeMention
in	O
Ashkenazi	O
Jews,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease

Susceptibility	O
to	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
in	O
twins:	O
the	O
role	O
of	O
genes,	O
HLA,	O
and	O
the	O
environment.	O
OBJECTIVE	O
	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	SpecificDisease
spondylitis	SpecificDisease
(	O
AS	SpecificDisease
).	O
METHODS	O
	O
Twins	O
with	O
AS	SpecificDisease
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	DiseaseClass
Diseases	DiseaseClass
database.	O
Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems.	O
HLA	O
typing	O
for	O
HLA-B27,	O
HLA-B60,	O
and	O
HLA-DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence-specific	O
primers,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers.	O
Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	SpecificDisease
.	O
RESULTS	O
	O
Six	O
of	O
8	O
monozygotic	O
(MZ)	O
twin	O
pairs	O
were	O
disease	O
concordant,	O
compared	O
with	O
4	O
of	O
15	O
B27-positive	O
dizygotic	O
(DZ)	O
twin	O
pairs	O
(27%)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(12.	O
5%).	O
Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease-concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins.	O
HLA-B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co-twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1.	O
Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97%	O
of	O
the	O
population	O
variance.	O
CONCLUSION	O
	O
Susceptibility	O
to	O
AS	SpecificDisease
is	O
largely	O
genetically	O
determined,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous.	O
HLA-B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	SpecificDisease

The	O
APCI1307K	O
allele	O
and	O
cancer	Modifier
risk	O
in	O
a	O
community-based	O
study	O
of	O
Ashkenazi	O
Jews.	O
Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
(	O
FAP	SpecificDisease
),	O
a	O
highly	O
penetrant	O
autosomal	DiseaseClass
dominant	DiseaseClass
disorder	DiseaseClass
characterized	O
by	O
multiple	O
intestinal	O
polyps	DiseaseClass
and,	O
without	O
surgical	O
intervention,	O
the	O
development	O
of	O
colorectal	SpecificDisease
cancer	SpecificDisease
(	O
CRC	SpecificDisease
).	O
APC	SpecificDisease
is	O
a	O
tumour-suppressor	O
gene,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	DiseaseClass
.	O
The	O
germline	O
T-to-A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307K	O
allele	O
converts	O
the	O
wild-type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(A8)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation.	O
The	O
I1307K	O
allele	O
was	O
found	O
in	O
6.	O
1%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	SpecificDisease
(ref.	O
2).	O
To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	DiseaseClass
,	O
we	O
genotyped	O
5,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey.	O
Risk	O
of	O
developing	O
colorectal,	CompositeMention
breast	CompositeMention
and	CompositeMention
other	CompositeMention
cancers	CompositeMention

The	O
hemochromatosis	Modifier
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding.	O
We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease
called	O
HFE.	O
The	O
gene	O
product,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I-like	O
family,	O
was	O
found	O
to	O
have	O
a	O
mutation,	O
Cys-282	O
--	O
>	O
Tyr	O
(C282Y),	O
in	O
85%	O
of	O
patient	O
chromosomes.	O
This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2-microglobulin	O
(beta2m)	O
and	O
prevents	O
cell-surface	O
expression.	O
A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association,	O
H63D,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant.	O
In	O
this	O
report,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild-type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild-type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(TfR).	O
The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR.	O
Studies	O
on	O
cell-associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild-type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin.	O
The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation.	O
Addition	O
of	O
soluble	O
wild-type	O
HFE/beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady-state	O
conditions,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells.	O
Furthermore,	O
at	O
4	O
degrees	O
C,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE/beta2m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration-dependent	O
manner.	O
Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin.	O
These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport,	O
the	O
TfR,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	SpecificDisease
hemochromatosis	SpecificDisease

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice-site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease
.	O
Patients	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1.	O
This	O
report	O
documents	O
a	O
novel	O
splice-site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	Modifier
dystrophy	Modifier
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat.	O
Using	O
methylation-sensitive	O
restriction	O
enzymes,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	SpecificDisease
dystrophy	SpecificDisease

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	Modifier
dystrophy	Modifier
patients.	O
The	O
genetic	O
basis	O
of	O
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	Modifier
protein	O
kinase	O
gene	O
on	O
chromosome	O
19.	O
One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	Modifier
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues.	O
This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease.	O
Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset.	O
In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	Modifier
CTG	O
repeat	O
somatic	O
instability,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	Modifier
dystrophy	Modifier

Inherited	SpecificDisease
colorectal	SpecificDisease
polyposis	SpecificDisease
and	O
cancer	Modifier
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism.	O
Germ-line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	Modifier
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	Modifier
tumor	Modifier
formation	O
in	O
familial	SpecificDisease
adenomatous	SpecificDisease
polyposis	SpecificDisease
syndrome	SpecificDisease
and	O
sporadic	O
colorectal	O
carcinogenesis,	O
respectively.	O
Recently,	O
an	O
isoleucine--	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(I1307K)	O
of	O
the	O
APC	Modifier
gene	O
has	O
been	O
identified	O
in	O
6%	O
-7%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population.	O
To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	Modifier
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	SpecificDisease
polyps	SpecificDisease
and.	O
or	O
colorectal	SpecificDisease
cancer,	SpecificDisease
for	O
the	O
APC	O
I1307K	O
polymorphism.	O
The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(10.	O
1%)	O
of	O
476	O
patients.	O
Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1.	O
5-1.	O
7	O
for	O
colorectal	SpecificDisease
neoplasia	SpecificDisease
(both	O
P	O
=.	O
01).	O
Furthermore,	O
compared	O
with	O
noncarriers,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	DiseaseClass
and	O
colorectal	SpecificDisease
cancers	SpecificDisease
per	O
patient	O
(P	O
=.	O
03),	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis.	O
We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	Modifier
formation	O
and	O
directly	O
contributes	O
to	O
3%	O
-4%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long-term-outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	Modifier
cancer	Modifier

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	DiseaseClass
malignancy	DiseaseClass
and	O
neurofibromatosis	SpecificDisease
type	SpecificDisease
1	SpecificDisease
.	O
Heterozygous	O
germ-line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	SpecificDisease
nonpolyposis	SpecificDisease
colorectal	SpecificDisease
cancer	SpecificDisease
.	O
The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild-type	O
alleles	O
is	O
unknown.	O
We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	Modifier
nonpolyposis	Modifier
colorectal	Modifier
cancer	Modifier
family	O
who	O
developed	O
hematological	DiseaseClass
malignancy	DiseaseClass
at	O
a	O
very	O
early	O
age,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	SpecificDisease
type	SpecificDisease
1	SpecificDisease
(	O
NF1	SpecificDisease
).	O
DNA	O
sequence	O
analysis	O
and	O
allele-specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(C676T--	O
>	O
Arg226Stop).	O
Thus,	O
a	O
homozygous	O
germ-line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	DiseaseClass
and/or	O
lymphoma	DiseaseClass
associated	O
with	O
neurofibromatosis	SpecificDisease
type	SpecificDisease
1	SpecificDisease

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	DiseaseClass
impairment	DiseaseClass
in	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
?	O
Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
DMD	SpecificDisease
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	DiseaseClass
impairment	DiseaseClass
observed	O
in	O
most	O
DMD	Modifier
patients.	O
Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	Modifier
promoters.	O
Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out.	O
Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence,	O
verbal	O
memory,	O
and	O
reading	O
skills.	O
Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	DiseaseClass
impairment	DiseaseClass
.	O
Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	DiseaseClass
dysfunction	DiseaseClass
.	O
These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and,	O
in	O
particular,	O
some	O
DMD	Modifier
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	DiseaseClass
impairment	DiseaseClass
associated	O
with	O
DMD	SpecificDisease

A	O
genome-wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	SpecificDisease
affective	SpecificDisease
disorder	SpecificDisease
among	O
the	O
Old	O
Order	O
Amish.	O
Bipolar	SpecificDisease
affective	SpecificDisease
disorder	SpecificDisease
(	O
BPAD	SpecificDisease
;	O
manic-depressive	SpecificDisease
illness	SpecificDisease
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	SpecificDisease
and/or	O
hypomania	SpecificDisease
interspersed	O
with	O
periods	O
of	O
depression	SpecificDisease
.	O
Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	SpecificDisease
.	O
To	O
date,	O
however,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	SpecificDisease
.	O
To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	SpecificDisease
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	DiseaseClass
disorders	DiseaseClass
,	O
we	O
used	O
mental	O
health	O
wellness	O
(absence	O
of	O
any	O
psychiatric	DiseaseClass
disorder	DiseaseClass
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome-wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	SpecificDisease
.	O
We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(maximum	O
GENEHUNTER-PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4.	O
05,	O
P	O
=	O
5.	O
22	O
x	O
10	O
(-4);	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(-5))	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(maximum	O
GENEHUNTER-PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3.	O
29,	O
P	O
=	O
2.	O
57	O
x	O
10	O
(-3);	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(-3))	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness.	O
These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	SpecificDisease
and	O
perhaps	O
other	O
related	O
affective	DiseaseClass
disorders	DiseaseClass

Hereditary	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
in	O
man.	O
I.	O
Clinical,	O
immunochemical,	O
and	O
family	O
studies.	O
The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	SpecificDisease
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
fifth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C5)	O
is	O
described.	O
The	O
proband,	O
a	O
20-year-old	O
black	O
female	O
with	O
systemic	SpecificDisease
lupus	SpecificDisease
erythematosus	SpecificDisease
since	O
age	O
11,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity,	O
even	O
during	O
remission.	O
C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays.	O
Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus,	O
but	O
C1,	O
C4,	O
C2,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations.	O
A	O
younger	O
half-sister,	O
who	O
had	O
no	O
underlying	O
disease,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5.	O
By	O
hemolytic	O
assay,	O
she	O
exhibited	O
1-2%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components.	O
C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half-normal,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	SpecificDisease
deficiency	SpecificDisease
.	O
Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5-deficient	Modifier
(	O
C5D	Modifier
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5.	O
In	O
specific	O
C5	O
titrations,	O
however,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	Modifier
serum,	O
curving	O
rather	O
than	O
linear	O
dose-response	O
plots	O
were	O
consistently	O
obtained,	O
suggesting	O
some	O
inhibitory	O
effect.	O
Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	Modifier
serum	O
contain	O
a	O
factor	O
(or	O
factors)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator.	O
Of	O
clinical	O
interest	O
are	O
(a)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	SpecificDisease
,	O
vasculitis	SpecificDisease
,	O
and	O
arthritis	DiseaseClass
in	O
an	O
individual	O
lacking	O
C5	O
(and	O
its	O
biologic	O
functions),	O
and	O
(b)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	DiseaseClass
infections	DiseaseClass
in	O
the	O
proband,	O
even	O
during	O
periods	O
of	O
low-dose	O
or	O
alternate-day	O
corticosteroid	O
therapy.	O
Other	O
observations	O
indicate	O
that	O
the	O
C5D	Modifier
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	DiseaseClass
infection	DiseaseClass

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia-telangiectasia	Modifier
(ATM)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes.	O
In	O
ataxia-telangiectasia	Modifier
(	O
A-T	Modifier
)	O
patients,	O
mutations	O
in	O
a	O
single	O
gene,	O
ATM,	O
result	O
in	O
an	O
autosomal	DiseaseClass
recessive	DiseaseClass
syndrome	DiseaseClass
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre-disposition	O
to	O
malignancy	DiseaseClass
.	O
Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A-T	SpecificDisease
but	O
may	O
be	O
cancer	Modifier
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity.	O
We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2-phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A-T	Modifier
patients,	O
13	O
obligate	O
A-T	Modifier
heterozygotes	O
(parents	O
of	O
the	O
patients),	O
and	O
14	O
normal	O
controls	O
following	O
X-irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers.	O
Both	O
A-T	Modifier
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation-induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls.	O
These	O
results	O
show	O
that	O
the	O
G2-phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A-T	Modifier
heterozygotes.	O
In	O
combination	O
with	O
molecular	O
genetic	O
analyses,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	CompositeMention
and	CompositeMention
sporadic	CompositeMention
cancers	CompositeMention
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	Modifier

The	O
molecular	O
basis	O
of	O
C6	SpecificDisease
deficiency	SpecificDisease
in	O
the	O
western	O
Cape,	O
South	O
Africa.	O
Deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
sixth	SpecificDisease
component	SpecificDisease
of	SpecificDisease
human	SpecificDisease
complement	SpecificDisease
(C6)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape,	O
South	O
Africa.	O
Meningococcal	SpecificDisease
disease	SpecificDisease
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	SpecificDisease
deficiency	SpecificDisease
(C6Q0)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease.	O
We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
	O
879delG,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported,	O
and	O
1195delC	O
and	O
1936delG,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African-Americans.	O
We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6/C7	O
region	O
DNA	O
marker	O
haplotypes,	O
although	O
small	O
variations	O
were	O
observed.	O
The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced.	O
The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape.	O
We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6-deficient	Modifier

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
.	O
Deficiency	SpecificDisease
of	SpecificDisease
arylsulfatase	SpecificDisease
A	SpecificDisease
(ARSA)	O
enzyme	O
activity	O
causes	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
).	O
A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	SpecificDisease
have	O
been	O
identified.	O
Recently,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	SpecificDisease
(Draghia	O
et	O
al.,	O
1997).	O
We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(f	O
=	O
0.	O
09,	O
n	O
=	O
61	O
subjects).	O
The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal.	O
It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	SpecificDisease

Piebaldism	SpecificDisease
with	O
deafness	SpecificDisease
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome.	O
In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	SpecificDisease
and	O
profound	O
congenital	O
sensorineural	SpecificDisease
deafness	SpecificDisease
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto-oncogene,	O
R796G.	O
Though	O
auditory	DiseaseClass
anomalies	DiseaseClass
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(W)	O
due	O
to	O
KIT	O
mutations,	O
deafness	SpecificDisease
is	O
not	O
typical	O
in	O
human	O
piebaldism	SpecificDisease
.	O
Thus,	O
the	O
occurrence	O
of	O
sensorineural	SpecificDisease
deafness	SpecificDisease
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	SpecificDisease
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	SpecificDisease
and	O
the	O
various	O
forms	O
of	O
Waardenburg	SpecificDisease
syndrome	SpecificDisease

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	Modifier
cancer	Modifier
families.	O
The	O
Breast	Modifier
Cancer	Modifier
Linkage	O
Consortium.	O
The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	SpecificDisease
breast	SpecificDisease
cancer	SpecificDisease
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
,	O
collected	O
by	O
the	O
Breast	Modifier
Cancer	Modifier
Linkage	O
Consortium.	O
Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	CompositeMention
or	CompositeMention
other	CompositeMention
cancers	CompositeMention
.	O
Overall,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52%	O
of	O
families,	O
to	O
BRCA2	O
in	O
32%	O
of	O
families,	O
and	O
to	O
neither	O
gene	O
in	O
16%	O
(95%	O
confidence	O
interval	O
[CI]	O
6%	O
-28%),	O
suggesting	O
other	O
predisposition	O
genes.	O
The	O
majority	O
(81%)	O
of	O
the	O
breast-ovarian	Modifier
cancer	Modifier
families	O
were	O
due	O
to	O
BRCA1,	O
with	O
most	O
others	O
(14%)	O
due	O
to	O
BRCA2.	O
Conversely,	O
the	O
majority	O
of	O
families	O
with	O
male	CompositeMention
and	CompositeMention
female	CompositeMention
breast	CompositeMention
cancer	CompositeMention
were	O
due	O
to	O
BRCA2	O
(76%).	O
The	O
largest	O
proportion	O
(67%)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	SpecificDisease
cancer	SpecificDisease
only.	O
These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data.	O
Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63%	O
(95%	O
CI	O
51%	O
-77%).	O
The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques.	O
The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2-mutation	O
families,	O
over	O
all	O
possible	O
penetrance	O
functions.	O
The	O
estimated	O
cumulative	O
risk	O
of	O
breast	SpecificDisease
cancer	SpecificDisease
reached	O
28%	O
(95%	O
CI	O
9%	O
-44%)	O
by	O
age	O
50	O
years	O
and	O
84%	O
(95%	O
CI	O
43%	O
-95%)	O
by	O
age	O
70	O
years.	O
The	O
corresponding	O
ovarian	Modifier
cancer	Modifier
risks	O
were	O
0.	O
4%	O
(95%	O
CI	O
0%	O
-1%)	O
by	O
age	O
50	O
years	O
and	O
27%	O
(95%	O
CI	O
0%	O
-47%)	O
by	O
age	O
70	O
years.	O
The	O
lifetime	O
risk	O
of	O
breast	SpecificDisease
cancer	SpecificDisease

Severe	O
early-onset	O
obesity	SpecificDisease
,	O
adrenal	DiseaseClass
insufficiency	DiseaseClass
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans.	O
Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre-pro-opiomelanocortin	O
(POMC)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(ACTH),	O
melanocyte-stimulating	O
hormones	O
(MSH)	O
alpha,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid-receptor	O
ligand	O
beta-endorphin.	O
While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	SpecificDisease
deficiency	SpecificDisease
have	O
been	O
reported	O
(OMIM	O
201400),	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far.	O
Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha-MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin-4-receptor	O
(MC4-R;	O
refs	O
3-5)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	SpecificDisease
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	SpecificDisease
.	O
The	O
dual	O
role	O
of	O
alpha-MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	SpecificDisease
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	SpecificDisease
deficiency	SpecificDisease
.	O
The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes.	O
Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(G7013T,	O
C7133delta)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha-MSH.	O
Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(C3804A)	O
which	O
abolishes	O
POMC	O
translation.	O
These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	DiseaseClass
defect	DiseaseClass
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	DiseaseClass
endocrine	DiseaseClass
disorder	DiseaseClass
resulting	O
in	O
early-onset	O
obesity	SpecificDisease
,	O
adrenal	DiseaseClass
insufficiency	DiseaseClass

The	O
tumor	Modifier
suppressor	O
gene	O
Smad4/Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo.	O
Mutations	O
in	O
the	O
SMAD4/DPC4	O
tumor	Modifier
suppressor	O
gene,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta-related	O
pathways,	O
are	O
involved	O
in	O
50%	O
of	O
pancreatic	SpecificDisease
cancers	SpecificDisease
.	O
Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7.	O
5	O
of	O
embryogenesis.	O
Mutant	O
embryos	O
have	O
reduced	O
size,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development.	O
Growth	DiseaseClass
retardation	DiseaseClass
of	O
the	O
Smad4-deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis.	O
Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild-type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	SpecificDisease
defect	SpecificDisease
.	O
These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	SpecificDisease
defect	SpecificDisease

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459+1G>A	O
within	O
a	O
family	O
with	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity.	O
In	O
a	O
family	O
with	O
three	O
siblings,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	SpecificDisease
leukodystrophy	SpecificDisease
(	O
MLD	SpecificDisease
),	O
fatal	O
at	O
age	O
5	O
years,	O
with	O
deficient	O
arylsulfatase	O
A	O
(ARSA)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(GS)	O
excretion.	O
The	O
two	O
other	O
siblings,	O
apparently	O
healthy	O
at	O
12	O
(1/2)	O
and	O
15	O
years,	O
respectively,	O
and	O
their	O
father,	O
apparently	O
healthy	O
as	O
well,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	Modifier
patients.	O
Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity.	O
The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0-type	O
mutation	O
459	O
+	O
1G	O
>	O
A,	O
and	O
from	O
his	O
father	O
a	O
novel,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(7delG).	O
The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and,	O
on	O
their	O
paternal	O
allele,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(A464V).	O
The	O
fathers	O
genotype	O
thus	O
was	O
7delG/A464V.	O
Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	Modifier
patients	O
and	O
50	O
controls.	O
A464V,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	SpecificDisease
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele.	O
Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	Modifier

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme.	O
Appreciable	O
beta	O
hexosaminidase	O
A	O
(hex	O
A)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	Modifier
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	SpecificDisease
of	SpecificDisease
hex	SpecificDisease
A	SpecificDisease
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay-Sachs	SpecificDisease
disease	SpecificDisease
(	O
TSD	SpecificDisease
).	O
Identification	O
and	O
quantitation	O
of	O
hex	O
A,	O
amounting	O
to	O
3.	O
5%	O
-6.	O
9%	O
of	O
total	O
beta	O
hexosaminidase	O
activity,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis,	O
DEAE-cellulose	O
ion-exchange	O
chromatography,	O
radial	O
immunodiffusion,	O
and	O
radioimmunoassay.	O
Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	Modifier
gene	O
and	O
a	O
rare	O
(allelic)	O
mutant	O
gene.	O
Thus,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A.	O
Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	Modifier
mutant.	O
However,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false-positive	O
prenatal	O
diagnosis	O
of	O
TSD	SpecificDisease
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	SpecificDisease
A	SpecificDisease
deficiency	SpecificDisease

A	O
mouse	O
model	O
for	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
imprinting-centre	O
mutations.	O
Imprinting	O
in	O
the	O
15q11-q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(IC),	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN.	O
Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader-Willi	SpecificDisease
syndrome	SpecificDisease
(	O
PWS	SpecificDisease
).	O
We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	SpecificDisease
and	O
the	O
mechanism	O
of	O
this	O
IC.	O
Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	SpecificDisease
.	O
Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS-IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(mouse	O
homologue	O
of	O
ZNF127),	O
Ndn	O
and	O
Ipw,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	Modifier

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease
represents	O
propagation	O
of	O
an	O
ancestral	O
allele.	O
Patients	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease
,	O
have	O
generalized	O
blistering	SpecificDisease
,	O
nail	SpecificDisease
dystrophy	SpecificDisease
,	O
patchy	SpecificDisease
alopecia	SpecificDisease
,	O
and	O
dental	DiseaseClass
abnormalities	DiseaseClass
.	O
Skin	DiseaseClass
fragility	DiseaseClass
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(COL17A1).	O
Recently,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	SpecificDisease
benign	SpecificDisease
epidermolysis	SpecificDisease
bullosa	SpecificDisease

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	Modifier
coproporphyria	Modifier
family.	O
Hereditary	SpecificDisease
coproporphyria	SpecificDisease
(	O
HCP	SpecificDisease
)	O
is	O
an	O
autosomal	DiseaseClass
dominant	DiseaseClass
disease	DiseaseClass
characterized	O
by	O
a	O
deficiency	SpecificDisease
of	SpecificDisease
coproporphyrinogen	SpecificDisease
oxidase	SpecificDisease
(CPO)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene.	O
Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	Modifier

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex,	O
properdin	O
factor	O
B,	O
and	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
second	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
.	O
The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	SpecificDisease
of	SpecificDisease
the	SpecificDisease
second	SpecificDisease
component	SpecificDisease
of	SpecificDisease
complement	SpecificDisease
(C2)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders.	O
Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	SpecificDisease
deficiency	SpecificDisease
.	O
12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	SpecificDisease
deficiency	SpecificDisease
were	O
found.	O
Of	O
57	O
informative	O
meioses,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	Modifier
deficiency	Modifier
gene	O
and	O
the	O
HLA-B	O
gene,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0.	O
035.	O
A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	SpecificDisease
deficiency	SpecificDisease
and	O
HLA-B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0.	O
04.	O
18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA-B	O
were	O
found.	O
Of	O
72	O
informative	O
meioses,	O
three	O
recombinants	O
were	O
found,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0.	O
042.	O
A	O
lod	O
score	O
of	O
16	O
between	O
HLA-B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0.	O
04.	O
A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA-D,	O
in	O
which	O
HLA-D	O
segregared	O
with	O
HLA-A	O
and	O
B.	O
These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	SpecificDisease
deficiency	SpecificDisease
are	O
located	O
outside	O
those	O
for	O
HLA,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA-A,	O
-B,	O
-D,	O
Factor	O
B	O
allotype,	O
C2	SpecificDisease
deficiency	SpecificDisease
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	SpecificDisease
deficiency	SpecificDisease
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3--5	O
centimorgans	O
from	O
the	O
HLA-A	O
and	O
HLA-B	O
loci,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	Modifier
deficiency	Modifier

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	Modifier
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	Modifier
phenotype.	O
We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	Modifier
phenotype.	O
In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	DiseaseClass
tumors	DiseaseClass
and,	O
as	O
a	O
result	O
of	O
linkage	O
analysis,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree.	O
A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys--	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon.	O
The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site.	O
Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co-segregated	O
with	O
patients	O
with	O
tumors	DiseaseClass

Complement	SpecificDisease
C7	SpecificDisease
deficiency	SpecificDisease
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes.	O
Seven	O
further	O
molecular	O
bases	O
of	O
C7	SpecificDisease
deficiency	SpecificDisease
are	O
described.	O
All	O
these	O
new	O
molecular	O
defects	O
involve	O
single-nucleotide	O
events,	O
deletions	O
and	O
substitutions,	O
some	O
of	O
which	O
alter	O
splice	O
sites,	O
and	O
others	O
codons.	O
They	O
are	O
distributed	O
along	O
the	O
C7	O
gene,	O
but	O
predominantly	O
towards	O
the	O
3	O
end.	O
All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals.	O
The	O
C6/C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	SpecificDisease
defects	SpecificDisease

Identification	O
of	O
constitutional	O
WT1	O
mutations,	O
in	O
patients	O
with	O
isolated	O
diffuse	SpecificDisease
mesangial	SpecificDisease
sclerosis	SpecificDisease
,	O
and	O
analysis	O
of	O
genotype/phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database.	O
Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene,	O
encoding	O
a	O
zinc-finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys-Drash	SpecificDisease
syndrome	SpecificDisease
(	O
DDS	SpecificDisease
),	O
or	O
diffuse	SpecificDisease
mesangial	SpecificDisease
sclerosis	SpecificDisease
(	O
DMS	SpecificDisease
)	O
associated	O
with	O
pseudohermaphroditism	SpecificDisease
and/or	O
Wilms	SpecificDisease
tumor	SpecificDisease
(	O
WT	SpecificDisease
).	O
Most	O
mutations	O
in	O
DDS	Modifier
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3,	O
respectively,	O
with	O
a	O
hot	O
spot	O
(R394W)	O
in	O
exon	O
9.	O
We	O
analyzed	O
a	O
series	O
of	O
24	O
patients,	O
10	O
with	O
isolated	SpecificDisease
DMS	SpecificDisease
(	O
IDMS	SpecificDisease
),	O
10	O
with	O
DDS	SpecificDisease
,	O
and	O
4	O
with	O
urogenital	DiseaseClass
abnormalities	DiseaseClass
and/or	O
WT	SpecificDisease
.	O
We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	SpecificDisease
.	O
One	O
male	O
and	O
two	O
female	O
IDMS	Modifier
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty.	O
Two	O
mutations	O
associated	O
with	O
IDMS	SpecificDisease
are	O
different	O
from	O
those	O
described	O
in	O
DDS	Modifier
patients.	O
No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	Modifier
patients,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease.	O
We	O
analyzed	O
genotype/phenotype	O
correlations,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ-line	O
mutations,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations,	O
according	O
to	O
the	O
different	O
symptoms.	O
This	O
demonstrated	O
(1)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	SpecificDisease
;	O
(2)	O
among	O
patients	O
with	O
DMS	SpecificDisease

Paternal	O
transmission	O
of	O
congenital	SpecificDisease
myotonic	SpecificDisease
dystrophy	SpecificDisease
.	O
We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	SpecificDisease
myotonic	SpecificDisease
dystrophy	SpecificDisease
(	O
DM	SpecificDisease
).	O
The	O
proband	O
is	O
a	O
23	O
year	O
old,	O
mentally	Modifier
retarded	Modifier
male	O
who	O
suffers	O
severe	O
muscular	DiseaseClass
weakness	DiseaseClass
.	O
He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth.	O
His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	SpecificDisease
.	O
Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	SpecificDisease
,	O
with	O
onset	O
around	O
30	O
years.	O
Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	SpecificDisease
DM	SpecificDisease
have	O
been	O
reported	O
recently.	O
We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	SpecificDisease
DM	SpecificDisease
.	O
Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	SpecificDisease
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	SpecificDisease
DM	SpecificDisease
.	O
Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed,	O
on	O
average,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	SpecificDisease
DM	SpecificDisease
.	O
We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	SpecificDisease
DM	SpecificDisease
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	SpecificDisease

Genomic	O
organization	O
of	O
the	O
UBE3A/E6-AP	O
gene	O
and	O
related	O
pseudogenes.	O
The	O
UBE3A	O
gene	O
encodes	O
the	O
E6-AP	O
ubiquitin-protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	Modifier
syndrome	Modifier
patients	O
who	O
lack	O
15q11-q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	SpecificDisease
disomy	SpecificDisease

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
.	O
Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery-Dreifuss	SpecificDisease
muscular	SpecificDisease
dystrophy	SpecificDisease
(	O
EDMD	SpecificDisease
).	O
It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina-associated	O
proteins	O
which	O
includes	O
LAP1,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(LBR).	O
A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(mAbs)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage-displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart.	O
Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels.	O
A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but,	O
after	O
affinity	O
purification	O
against	O
a	O
pure-emerin	O
band	O
on	O
a	O
western	O
blot,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane.	O
These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and,	O
therefore,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	DiseaseClass
defects	DiseaseClass
in	O
EDMD	SpecificDisease
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs.	O
Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei,	O
it	O
was	O
absent	O
from	O
many	O
non-myocyte	O
cells	O
in	O
the	O
heart.	O
This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	SpecificDisease
.	O
In	O
contrast,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina.	O
Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei.	O
In	O
EDMD	SpecificDisease

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high-grade,	O
non-inherited	SpecificDisease
breast	SpecificDisease
carcinomas	SpecificDisease
.	O
Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	Modifier
-suppressor	O
gene	O
and	O
hereditary	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancer	CompositeMention
is	O
established,	O
the	O
role,	O
if	O
any,	O
of	O
BRCA1	O
in	O
non-familial	DiseaseClass
cancers	DiseaseClass
is	O
unclear.	O
BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	DiseaseClass
cancers	DiseaseClass
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non-familial	CompositeMention
breast	CompositeMention
and	CompositeMention
ovarian	CompositeMention
cancers	CompositeMention
.	O
Epigenetic	O
loss,	O
however,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear,	O
to	O
conditionally	O
nuclear,	O
to	O
the	O
ER/golgi,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus.	O
In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti-BRCA1	O
antibodies.	O
These	O
reagents	O
detect	O
a	O
220-kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines,	O
including	O
those	O
derived	O
from	O
breast	SpecificDisease
malignancies	SpecificDisease
.	O
Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast,	O
invasive	DiseaseClass
lobular	DiseaseClass
cancers	DiseaseClass
and	O
low-grade	SpecificDisease
ductal	SpecificDisease
carcinomas	SpecificDisease
.	O
Conversely,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high-grade,	O
ductal	SpecificDisease
carcinomas	SpecificDisease
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	SpecificDisease
breast	SpecificDisease
cancers	SpecificDisease

